U.S. IVD Consumables Market to Reach USD 63.41B by 2035

Market Outlook

By 2035, the U.S. IVD Consumables Market is expected to reach approximately USD 63.41 billion, expanding at a CAGR of 7.35% during the forecast period 2026–2035. The market was valued at approximately USD 31.20 billion in 2025, while the historical assessment covers 2021 through 2024. All market values in this report are expressed in USD billions.

The U.S. in vitro diagnostic consumables industry represents the recurring-revenue foundation of the country’s clinical testing ecosystem. Unlike diagnostic instruments, which are purchased through multiyear capital cycles, consumables are replenished continuously according to test volume. The market includes diagnostic reagents, assay kits, cartridges, cassettes, test strips, calibrators, controls, sample-preparation materials, extraction consumables, specimen collection products, transport media, and other single-use components required to generate patient results across centralized laboratories, hospitals, physician offices, urgent care centers, pharmacies, outpatient facilities, and home-testing settings.

Demand is supported by the extraordinary scale of laboratory medicine in the United States. Approximately 320,000 laboratory entities operate under the Clinical Laboratory Improvement Amendments framework, creating one of the world’s largest installed bases for recurring diagnostic reagent and consumable utilization. The addressable testing pool is further reinforced by high rates of diabetes, cancer, chronic kidney disease, cardiovascular disease, respiratory infection, sepsis, sexually transmitted infections, and age-related conditions that require repeat laboratory monitoring rather than one-time testing.

The historical market did not move in a straight line because the COVID-19 testing cycle temporarily changed the revenue mix of U.S. diagnostics. The market is estimated at approximately USD 29.65 billion in 2021 and USD 31.10 billion in 2022, when molecular reagents, rapid antigen tests, collection swabs, transport media, extraction consumables, and respiratory testing cartridges were operating at exceptional volumes. The market normalized to approximately USD 27.90 billion in 2023 as pandemic-specific demand declined, before recovering to approximately USD 29.45 billion in 2024 as routine clinical chemistry, immunoassay, oncology, molecular, microbiology, diabetes, and respiratory testing regained momentum.

By 2025, the market reached approximately USD 31.20 billion, moving above its pandemic-era peak on a more diversified revenue base. The next growth cycle is materially different from the COVID testing surge. Expansion through 2035 will be driven by higher-value molecular assays, multiplex infectious disease panels, companion diagnostics, oncology biomarkers, blood-based neurological testing, automated immunoassays, continuous test-menu expansion, decentralized PCR, chronic disease monitoring, and growing use of disposable cartridges that shift laboratory complexity into manufacturer-controlled consumable formats.

The market is projected to reach approximately USD 33.49 billion in 2026, USD 44.48 billion by 2030, and USD 63.41 billion by 2035. The strongest commercial advantage will remain with manufacturers that combine a large analyzer installed base with proprietary consumables because every instrument placement creates a recurring reagent annuity. Consequently, hospital procurement decisions increasingly evaluate analyzers according to lifetime reagent economics, test-menu breadth, turnaround time, labor requirements, quality-control burden, connectivity, reagent stability, and the ability to consolidate multiple diagnostic disciplines onto fewer platforms.

Introduction

According to the U.S. IVD Consumables Market Report, diagnostic consumables occupy a strategically different position from most medical-device categories. A hospital can defer replacement of an analyzer or laboratory automation line during a capital-constrained year, but it cannot stop buying reagents, controls, calibrators, cartridges, tips, tubes, and collection materials without interrupting patient care. This recurring clinical requirement gives the market a comparatively resilient demand profile even when hospital capital budgets tighten.

The United States combines a large testing infrastructure with high chronic-disease prevalence and extensive reimbursement coverage. Clinical laboratories operate across academic medical centers, integrated health systems, national reference laboratories, physician offices, community hospitals, public health laboratories, pharmacies, urgent care networks, ambulatory facilities, and decentralized testing sites. The breadth of these settings supports both high-throughput bulk reagents and premium single-use cartridge models.

Clinical chemistry and immunoassay remain foundational volume categories, but value growth is shifting toward molecular diagnostics and specialized assays. The U.S. Medicare Clinical Laboratory Fee Schedule contained more than 2,100 laboratory test records during 2025, illustrating the breadth and continuing expansion of reimbursable diagnostic procedures. Every additional covered assay category creates potential demand for dedicated reagents, controls, calibrators, extraction materials, specimen-processing products, and platform-specific cartridges.

Chronic disease provides a substantial testing base. Current U.S. estimates indicate that more than 40 million people have diabetes and more than 115 million adults have prediabetes. This creates recurring demand for glucose assays, HbA1c testing, kidney-function monitoring, lipid testing, urine albumin assessment, ketone testing, and associated chemistry consumables. Chronic kidney disease affects more than 35 million U.S. adults, further increasing utilization of creatinine, eGFR-supporting chemistry tests, electrolyte panels, urine protein testing, anemia monitoring, and other recurring laboratory procedures.

Oncology is becoming one of the highest-value areas of IVD consumable development. Approximately 2.04 million new cancer cases were projected in the United States during 2025, creating demand for histopathology reagents, immunohistochemistry antibodies, molecular panels, companion diagnostics, fluorescence assays, circulating tumor DNA tests, genomic sample-preparation products, and treatment-monitoring assays. The economic value per oncology test is substantially higher than routine chemistry, making oncology a disproportionately important contributor to value growth even though its absolute test volume is lower.

The U.S. market is therefore transitioning from a laboratory model defined mainly by high-volume routine testing to one combining high volume with increasing diagnostic specificity. Procurement leaders want fewer manual steps, standardized reagent packs, longer onboard stability, automated quality control, reduced waste, consolidated test menus, and rapid addition of new biomarkers. Manufacturers capable of providing these characteristics can command attractive recurring consumable revenue while making it more difficult for laboratories to change platforms.

From 2026 through 2035, the central commercial question will not be whether laboratory testing volume increases. The more important issue will be where value migrates within the testing workflow. Routine commodity assays will remain essential but will face stronger pricing pressure. Proprietary molecular cartridges, companion diagnostic assays, neurological biomarkers, syndromic panels, digital PCR reagents, transplant monitoring assays, and high-sensitivity immunoassays should capture a progressively larger portion of market value.

Key Market Drivers: What’s Fueling the U.S. IVD Consumables Market Boom?

The first major driver is the scale and frequency of chronic disease testing. Diabetes demonstrates the recurring-consumption economics particularly clearly. More than 40 million Americans are estimated to have diabetes, while over 115 million adults have prediabetes. These populations require repeated blood glucose, HbA1c, lipid, renal, liver, and urine testing across primary care, endocrinology, hospital, pharmacy, and home environments. Unlike episodic diagnostic procedures, chronic disease surveillance creates predictable replenishment demand throughout the year.

Kidney disease adds another recurring diagnostic layer. More than 35.5 million U.S. adults are estimated to have chronic kidney disease, while diabetes and hypertension remain major causes of renal failure. These patients generate repeated demand for creatinine reagents, electrolyte assays, albumin tests, urine strips, anemia-related assays, and other laboratory consumables. As U.S. healthcare moves toward earlier kidney-disease detection, routine laboratory panels become part of preventive care rather than only late-stage disease management.

A second major driver is infectious disease testing. The United States experiences substantial annual respiratory disease burden even outside pandemic conditions. During the 2023–2024 influenza season, approximately 40 million influenza illnesses, 18 million medical visits, 470,000 hospitalizations, and 28,000 deaths were estimated. Each respiratory season produces demand for rapid antigen consumables, molecular cartridges, multiplex PCR panels, transport media, specimen swabs, extraction reagents, and quality-control materials.

Hospital infection management also supports recurring testing. Approximately 1.7 million U.S. adults experience sepsis hospitalization in a typical year, with roughly 350,000 dying in the hospital or being discharged to hospice. Sepsis workflows require blood cultures, lactate testing, antimicrobial susceptibility testing, inflammatory biomarkers, molecular pathogen identification, CBC testing, coagulation studies, and repeated chemistry panels. Diagnostic manufacturers that reduce time to actionable organism identification can create meaningful clinical and hospital-economic value.

A third driver is the expansion of molecular testing beyond infectious diseases. Molecular diagnostics are increasingly used in oncology, transplant medicine, hereditary disease, women’s health, virology, pharmacogenomics, and therapy selection. The commercial advantage of molecular testing for consumable suppliers is particularly attractive because each run often requires proprietary reaction cartridges, primers, probes, master mixes, extraction kits, internal controls, and single-use plastics that cannot be substituted easily.

A fourth driver is the growth of personalized oncology. Approximately 2.04 million new cancer cases were projected in the United States in 2025. Drug labels are becoming more dependent on biomarker-defined patient populations, making diagnostic testing a prerequisite for treatment decisions. Companion diagnostic assays for HER2, PD-L1, EGFR, ALK, BRAF, BRCA, KRAS, NTRK, PTEN, and other biomarkers create high-value recurring reagent opportunities in pathology and molecular laboratories.

A fifth driver is decentralization. Testing is steadily moving beyond core laboratories into emergency departments, urgent care centers, physician practices, pharmacies, retail clinics, and selected home settings. The economics of decentralized testing favor self-contained cartridges and cassettes because they minimize operator training, contamination risk, manual pipetting, and quality-control complexity. For manufacturers, this changes value capture from low-cost bulk reagent supply toward higher-priced per-test consumables.

A sixth driver is laboratory staffing pressure. U.S. laboratories continue to prioritize automation because shortages of qualified medical laboratory personnel make labor-intensive workflows increasingly difficult to sustain. Ready-to-use reagent packs, automated sample preparation, integrated cartridges, onboard calibration, and random-access testing reduce hands-on time. When laboratories calculate total cost per reportable result, an apparently more expensive consumable can become economically attractive if it reduces labor, reruns, waste, repeat phlebotomy, or turnaround time.

A seventh driver is the size of the regulated testing infrastructure. CLIA covers approximately 320,000 laboratory entities. This creates a broad customer base ranging from national reference laboratories to small certificate-of-waiver sites. Manufacturers can therefore pursue multiple pricing and distribution strategies: large-volume enterprise contracts for integrated delivery networks, reagent-rental agreements for hospital laboratories, cartridge models for decentralized sites, distributor-led supply for physician offices, and direct-to-consumer channels for selected over-the-counter tests.

Reimbursement remains both a driver and a constraint. Medicare pays most clinical diagnostic laboratory tests through the Clinical Laboratory Fee Schedule, and payment methodology continues to influence laboratory purchasing behavior. Manufacturers must increasingly demonstrate that a new consumable is not merely analytically superior but economically viable under current payment levels. Tests that prevent unnecessary imaging, accelerate antimicrobial treatment, enable targeted oncology therapy, or reduce hospital length of stay are better positioned to defend premium consumable pricing.

Innovation in Focus: How Manufacturers Are Raising the Bar?

Innovation in the U.S. IVD consumables market is increasingly centered on placing more clinical information into each consumable rather than simply increasing test volume. This is changing the economics of the industry. The traditional model used relatively low-cost reagents to generate one analyte result. Newer platforms can use a single cartridge or reagent set to evaluate multiple pathogens, genetic alterations, biomarkers, or disease signatures, increasing the clinical value created per test.

Syndromic molecular testing is one of the clearest examples. Multiplex respiratory, gastrointestinal, meningitis, bloodstream infection, and sore-throat panels can detect several potential causes of disease from a single specimen. In 2024, an FDA-cleared and CLIA-waived BIOFIRE SPOTFIRE respiratory/sore-throat panel demonstrated the direction of this market by enabling detection of up to 15 respiratory and throat pathogens or subtypes in approximately 15 minutes. The commercial implication is important: high-complexity molecular testing is increasingly being converted into standardized disposable cartridges usable closer to the patient.

Neurology is emerging as another premium diagnostic frontier. In May 2025, the FDA cleared the first blood-based IVD intended to aid in diagnosing Alzheimer’s disease. The Lumipulse plasma assay evaluates pTau217 and beta-amyloid-related markers to help assess amyloid pathology in symptomatic adults aged 55 and older. Blood-based neurological biomarkers could create a new recurring immunoassay consumables category by shifting portions of diagnostic evaluation away from more invasive cerebrospinal fluid collection and expensive PET imaging.

Precision oncology is accelerating consumable innovation in pathology. Immunohistochemistry is moving from qualitative staining toward quantitative treatment-selection workflows supported by digital pathology and algorithmic interpretation. Manufacturers are developing companion diagnostic antibodies and reagent systems linked to specific targeted therapies, raising the strategic value of proprietary pathology consumables.

Automation within the consumable itself is another important design trend. Sample preparation historically required separate extraction reagents, pipette tips, tubes, wash buffers, and skilled technologists. Integrated cartridges can now combine lysis, extraction, amplification, detection, and quality control in a closed format. This raises consumable price per test but lowers operator burden and can expand molecular testing into lower-complexity environments.

Manufacturers are also engineering reagent stability more aggressively. Longer onboard stability reduces reagent waste for laboratories with variable test demand. Smaller reagent pack sizes can improve economics for community hospitals, while large high-throughput packs benefit national laboratories. Packaging configuration is therefore becoming a competitive variable rather than a logistics afterthought.

Quality-control and calibration consumables are becoming more important as laboratories consolidate analyzers and expand menus. Automated analyzers may run hundreds or thousands of patient tests each day, making reliable calibration and quality assurance essential. Vendors that integrate controls, calibrators, lot traceability, remote monitoring, and automated QC workflows create additional switching barriers because laboratory validation extends beyond the core reagent.

Regulatory strategy is also shaping innovation. The federal approach toward laboratory-developed tests changed materially after the FDA’s 2024 final rule was vacated by a federal district court in March 2025 and FDA subsequently restored the prior regulatory text. This increases strategic importance for FDA-cleared or approved manufacturer-developed IVDs while preserving a complex competitive relationship between commercial kits and laboratory-developed testing.

The strongest manufacturers are therefore building closed-loop diagnostic ecosystems in which instruments, reagents, calibrators, controls, software, service, workflow automation, and clinical evidence reinforce one another. The consumable is no longer a simple disposable input. It is increasingly the commercial mechanism through which a manufacturer captures the value of its installed platform.

Segmentation Insights

The U.S. IVD Consumables Market is segmented on the basis of product type, diagnostic technology, application, end user, and region.

By Product Type

Reagents and Assay Kits

Reagents and assay kits represent the largest product category because virtually every centralized laboratory discipline depends on recurring chemical, enzymatic, immunologic, microbiologic, or molecular reagents. The segment includes clinical chemistry reagents, immunoassay reagents, PCR reaction mixes, antibodies, stains, culture reagents, coagulation reagents, hematology solutions, sequencing-related reagents, and specialized diagnostic kits.

The category benefits from the installed-base model used by major IVD manufacturers. Once a laboratory standardizes on an analyzer family, changing reagent suppliers can require method validation, staff retraining, interface work, quality-control changes, and potentially new capital investment. This creates high recurring revenue retention for manufacturers with broad test menus.

Cartridges, Cassettes, Test Strips, and Single-Use Test Devices

Disposable cartridges and cassettes are expected to be among the fastest-growing consumable categories through 2035. These products are central to molecular point-of-care testing, blood gas analysis, cardiac biomarker testing, infectious disease testing, urinalysis, pregnancy testing, glucose monitoring, and other decentralized workflows.

Their value proposition is workflow simplification. A closed cartridge can incorporate reagent storage, sample processing, reaction chambers, detection chemistry, and waste containment. This reduces contamination risk and makes sophisticated testing possible outside traditional high-complexity laboratories. Hospitals and outpatient sites frequently accept higher consumable prices when faster turnaround materially changes clinical decisions.

Calibrators and Quality-Control Materials

Calibrators and controls form a smaller but highly defensible recurring segment. U.S. laboratories must demonstrate analytical performance and quality, making QC materials essential rather than discretionary. Demand expands as laboratories add assays, instruments, shifts, and testing locations.

Third-party quality-control suppliers compete with analyzer manufacturers, particularly in laboratories that want independent verification of assay performance. Growth is also supported by increasing regulatory scrutiny, accreditation requirements, proficiency testing, and the need to document consistency across multi-hospital networks.

Sample Preparation and Extraction Consumables

Sample preparation includes extraction kits, purification reagents, nucleic-acid isolation materials, beads, columns, reaction plates, specialized tubes, and single-use plastics. Demand is strongest in molecular diagnostics, genomics, infectious disease testing, oncology, and transplant medicine.

Automation is shifting the mix from manually assembled sample-preparation workflows toward standardized kits designed for specific extraction platforms. High-throughput laboratories prioritize yield, reproducibility, contamination control, and automation compatibility, while decentralized systems increasingly embed sample preparation directly into a cartridge.

Specimen Collection, Transport, and Ancillary Consumables

This segment includes swabs, blood collection tubes, specimen containers, transport media, lancets, capillary collection devices, sample cups, transfer devices, and other components used before the analytical stage. Although unit prices are lower than molecular cartridges, enormous testing volumes make this category strategically significant.

Demand is closely tied to phlebotomy volumes, respiratory testing, women’s health, microbiology, home collection, and decentralized diagnostics. The continued development of blood-based molecular tests and remote specimen collection is expected to increase demand for collection products designed to stabilize analytes during transport.

By Diagnostic Technology

Immunoassay

Immunoassay represents one of the largest consumable revenue pools in U.S. laboratory diagnostics. Applications include thyroid testing, cardiac biomarkers, reproductive hormones, infectious disease serology, tumor markers, vitamin testing, therapeutic drug monitoring, neurological biomarkers, and autoimmune testing.

Growth is increasingly driven by high-sensitivity and specialty assays rather than basic menu expansion. New neurological, oncology, cardiac, and inflammatory biomarkers can generate premium reagent revenue because they often address unmet clinical needs and initially have limited competitive alternatives.

Clinical Chemistry

Clinical chemistry remains the highest-volume routine testing category. Reagents are consumed daily for glucose, renal function, liver function, electrolytes, lipids, proteins, enzymes, and metabolic testing. Chronic disease prevalence ensures a stable baseline even though pricing competition is intense.

Large integrated health systems increasingly consolidate chemistry and immunoassay onto automated platforms. Manufacturers therefore compete on reagent cost per reportable result, throughput, reagent stability, calibration frequency, automated inventory management, and ability to reduce laboratory footprint.

Molecular Diagnostics and PCR

Molecular diagnostics are expected to generate one of the highest CAGRs in the consumables market. Reagents and cartridges support infectious disease, oncology, hereditary testing, transplant monitoring, women’s health, pharmacogenomics, and blood screening.

Molecular tests typically generate substantially more consumable revenue per result than routine chemistry. Multiplexing further increases commercial value by allowing a single cartridge to detect numerous targets. The growing availability of CLIA-waived molecular platforms is expanding the addressable market beyond centralized laboratories.

Hematology and Coagulation

Hematology consumables include diluents, lysing reagents, stains, controls, calibrators, and related products used for complete blood counts and cellular analysis. Coagulation consumables include PT/INR, aPTT, fibrinogen, D-dimer, anti-Xa, specialty factor, and thrombophilia reagents.

This segment remains deeply embedded in hospital workflow because hematology and coagulation testing support emergency medicine, oncology, surgery, intensive care, anticoagulation management, obstetrics, and inpatient monitoring. Growth is steady rather than explosive, but recurring volume and clinical necessity create attractive revenue stability.

Microbiology

Microbiology consumables include culture media, identification reagents, antimicrobial susceptibility products, blood-culture bottles, stains, rapid antigen assays, and molecular pathogen panels. Rising concern regarding antimicrobial resistance makes faster organism identification increasingly valuable.

Hospitals are linking microbiology investment to antimicrobial stewardship. Solutions that shorten time from specimen collection to organism identification and susceptibility result can influence antibiotic use, isolation decisions, length of stay, and infection-control operations.

Urinalysis and Other Specialized Diagnostics

Urinalysis includes reagent strips, microscopy consumables, cartridges, controls, and associated products used in kidney disease, diabetes, urinary tract infection, pregnancy, and general health assessment. Specialized testing includes autoimmune assays, allergy diagnostics, toxicology, therapeutic drug monitoring, reproductive testing, and selected genetic applications.

These categories benefit from routine outpatient demand and from automation that converts historically manual procedures into standardized analyzable consumables.

By Application

Infectious Diseases

Infectious disease is one of the most strategically important application segments. The U.S. requires continuous testing for influenza, RSV, SARS-CoV-2, streptococcal infection, gastrointestinal pathogens, sexually transmitted infections, HIV, hepatitis, tuberculosis, bloodstream infections, and healthcare-associated pathogens.

The segment has moved beyond single-pathogen testing toward syndromic and multiplex approaches. Rapid molecular identification can affect isolation decisions, antibiotic selection, antiviral treatment, and emergency department throughput. This clinical impact supports premium cartridge economics.

Diabetes and Metabolic Disorders

Diabetes and metabolic disease represent a high-volume application because more than 40 million Americans have diabetes and more than 115 million adults have prediabetes. Consumables include glucose reagents and strips, HbA1c reagents, ketone tests, lipid panels, renal markers, urine albumin assays, and other metabolic monitoring products.

The category is particularly attractive because testing occurs repeatedly across the patient journey. Screening, diagnosis, therapy adjustment, complication surveillance, and inpatient management all generate recurring consumption.

Oncology and Companion Diagnostics

Oncology is expected to be one of the fastest-growing value segments. Approximately 2.04 million new U.S. cancer cases were projected in 2025. Diagnostic consumables support pathology, immunohistochemistry, cytology, molecular profiling, treatment selection, minimal residual disease assessment, and disease monitoring.

As pharmaceutical development becomes more biomarker-specific, testing increasingly determines eligibility for treatment. This strengthens the negotiating position of assay manufacturers whose tests are incorporated into therapy pathways.

Cardiovascular and Critical Care

Consumables used in cardiac and critical-care testing include troponin, BNP or NT-proBNP, D-dimer, blood gas, lactate, electrolyte, coagulation, inflammatory marker, and chemistry reagents. Emergency departments and intensive care units prioritize rapid turnaround because results can immediately change treatment.

Point-of-care formats are especially important in this application. Higher per-test consumable pricing can be justified when bedside or near-patient testing reduces time to intervention.

Renal, Liver, and Other Chronic Disease Testing

Chronic kidney disease affects more than 35 million U.S. adults, supporting large recurring demand for creatinine, electrolyte, albumin, urine, anemia, and metabolic testing. Liver disease similarly requires enzymes, bilirubin, viral hepatitis tests, coagulation markers, and specialized monitoring.

The chronic nature of these diseases gives the segment recurring rather than episodic demand. Preventive screening initiatives could further increase test frequency before patients reach advanced disease.

Women’s Health, Genetic, and Reproductive Testing

Women’s health includes pregnancy testing, prenatal screening, HPV testing, sexually transmitted infection testing, reproductive hormones, cervical cancer screening, and genetic risk assessment. Molecular testing is raising average revenue per test through HPV genotyping, prenatal screening, carrier testing, and reproductive genetics.

The increasing movement toward earlier risk identification should support continued consumable demand across hospital laboratories, specialty practices, and reference laboratories.

By End User

Hospitals and Hospital Laboratories

Hospitals and integrated health systems represent the largest end-user segment. They consume broad portfolios spanning chemistry, immunoassay, hematology, coagulation, microbiology, molecular testing, blood gas, pathology, and point-of-care diagnostics.

Procurement is increasingly centralized across integrated delivery networks. Hospitals want to standardize platforms across multiple facilities to reduce training, inventory complexity, service contracts, and quality-control variation. This gives large suppliers with broad test menus an advantage in enterprise agreements.

Independent and Reference Laboratories

National and regional reference laboratories represent extremely high-volume consumable purchasers. Their economics emphasize reagent cost, automation, throughput, analyzer uptime, specimen logistics, menu depth, and labor efficiency.

These laboratories are particularly important for advanced molecular diagnostics, esoteric testing, oncology, genetics, pathology, and tests that community hospitals cannot economically perform in-house. Their scale gives them significant purchasing leverage, but it also makes reliable reagent supply strategically critical.

Physician Offices, Urgent Care, and Other Near-Patient Settings

Physician offices and urgent care centers are expanding their use of CLIA-waived and simplified diagnostics. Respiratory infection testing, strep testing, pregnancy testing, urinalysis, HbA1c, lipid testing, and selected molecular assays can provide results during the patient encounter.

These sites favor self-contained cartridges, cassettes, and test kits because staffing models cannot support complex laboratory procedures. Ease of use, room-temperature storage, fast turnaround, and simple quality-control requirements are major purchasing criteria.

Retail, Pharmacy, and Home Testing

Consumer-facing diagnostics expanded materially during the pandemic and are now developing into a broader testing channel. At-home pregnancy, glucose, COVID-19, HIV, and selected specimen-collection products have established consumer familiarity with self-testing.

Long-term opportunity depends on regulatory authorization, clinical usefulness, reimbursement, ease of interpretation, and connectivity to healthcare providers. Home collection linked to centralized molecular testing is another emerging consumable model.

Public Health, Blood Banks, Academic, and Specialty Laboratories

Public health laboratories use infectious disease reagents, sequencing consumables, confirmatory tests, and surveillance products. Blood banks consume high volumes of infectious disease screening reagents, immunohematology products, controls, and collection materials.

Academic medical centers and specialty laboratories play an outsized role in adoption of new biomarkers. Their early use of oncology, neurology, transplantation, genetics, and specialized molecular consumables can influence subsequent community adoption.

Regional Insights: Where the Market is Growing Fastest

The U.S. IVD Consumables Market is geographically segmented into the South, Northeast, West, and Midwest. Regional demand differs according to population, age profile, chronic disease prevalence, hospital and laboratory density, infectious disease burden, academic medical center concentration, payer mix, population growth, and adoption of decentralized testing.

The South represents the largest market in 2025, while the West is expected to post the fastest growth through 2035. The Northeast remains a premium market for specialized molecular, oncology, pathology, and academic laboratory testing. The Midwest provides a large, stable foundation of hospital and chronic disease diagnostic demand.

South

The South represents an estimated USD 12.05 billion of U.S. IVD consumable revenue in 2025, or close to 39% of the national market. The region includes Texas, Florida, Georgia, North Carolina, South Carolina, Virginia, Maryland, Delaware, West Virginia, Kentucky, Tennessee, Alabama, Mississippi, Louisiana, Arkansas, Oklahoma, and the District of Columbia under the broader commercial market mapping used in this report.

Population scale is the largest structural advantage. Texas reached approximately 31.7 million residents in 2025, while Florida exceeded 23.4 million. Georgia and North Carolina each exceeded 11 million residents. Texas, Florida, North Carolina, Georgia, South Carolina, Tennessee, and Virginia have also been among the important contributors to U.S. population growth, increasing the long-term testing base.

Texas is the largest IVD consumables opportunity in the region. Houston, Dallas-Fort Worth, Austin, and San Antonio contain large integrated delivery networks, cancer centers, transplant programs, pathology laboratories, infectious disease programs, and high-volume outpatient networks. The state’s population increased by nearly 391,000 between mid-2024 and mid-2025, reinforcing recurring demand for routine and specialized testing.

Florida is another highly attractive market because its population size is combined with a large older adult demographic. This supports chemistry, immunoassay, oncology, cardiac, renal, infectious disease, and neurological testing. Florida also reported one of the country’s highest acute hepatitis C rates in recent CDC surveillance, strengthening demand for screening and confirmatory infectious disease assays.

North Carolina and Georgia are increasingly important because of rapid population growth and sophisticated academic and biopharmaceutical ecosystems. North Carolina added approximately 146,000 residents between 2024 and 2025, while Georgia added nearly 99,000. Large health systems in both states continue to invest in laboratory automation, molecular diagnostics, oncology, and decentralized testing.

Tennessee, Kentucky, West Virginia, Alabama, Mississippi, Louisiana, and Arkansas present a different opportunity profile. Several have elevated chronic disease and infectious disease burdens, creating substantial need for diabetes, hepatitis, renal, cardiovascular, and hospital testing. West Virginia reported an acute hepatitis C rate of 6.4 cases per 100,000 in 2023 and Kentucky 5.9, well above the national reported rate of 1.5.

The South is also disproportionately important for HIV testing. Recent CDC estimates indicate that close to half of new U.S. HIV infections occur in the South. This makes the region strategically important for HIV screening, confirmatory testing, viral-load monitoring, sexually transmitted infection diagnostics, and public-health testing programs.

The region is expected to remain the largest market through 2035, potentially reaching approximately USD 24.98 billion. Expansion will be driven by demographic growth, chronic disease screening, respiratory testing, oncology diagnostics, reference-laboratory investment, urgent-care expansion, and broader deployment of CLIA-waived molecular platforms.

West

The West represents an estimated USD 6.65 billion market in 2025 and is expected to grow faster than the national average, potentially reaching approximately USD 14.35 billion by 2035. The region includes California, Washington, Oregon, Arizona, Nevada, Colorado, Utah, New Mexico, Idaho, Montana, Wyoming, Alaska, and Hawaii.

California is the largest state market in the region and the largest individual state IVD opportunity nationally. Its approximately 39.4 million residents in 2025, extensive academic medical infrastructure, biotechnology sector, oncology centers, reference laboratories, health technology companies, and large managed-care organizations create demand across virtually every IVD category.

California is particularly influential in molecular diagnostics, oncology testing, genomics, reproductive health, transplant diagnostics, and digital laboratory workflows. Many emerging diagnostics achieve early clinical adoption through California academic and specialty centers before spreading to broader U.S. markets.

Arizona, Nevada, Utah, Idaho, and Washington are important growth states because of continuing population expansion. Washington exceeded 8 million residents in 2025, Arizona reached approximately 7.6 million, and Utah and Idaho remained among the faster-growing states on a percentage basis. Population migration increases basic laboratory demand while health systems simultaneously expand outpatient and hospital capacity.

Washington and Oregon have sophisticated integrated delivery networks that favor standardization, automation, and digital connectivity. These markets are attractive for premium consumables where manufacturers can demonstrate labor savings or consolidation of testing platforms.

Colorado and Utah have strong academic, genomic, and specialty medicine ecosystems. They are favorable markets for molecular diagnostics, oncology, infectious disease testing, and decentralized testing technologies. Utah also appears among states with comparatively elevated recent acute hepatitis C rates, supporting viral hepatitis testing requirements.

The West should gain national market share as blood-based diagnostics, advanced molecular assays, genomics, precision oncology, and digitally connected point-of-care systems become larger contributors to total IVD revenue.

Northeast

The Northeast represents an estimated USD 6.85 billion in IVD consumable revenue in 2025 and remains one of the country’s highest-value diagnostic regions on a per-patient basis. The region includes New York, Pennsylvania, New Jersey, Massachusetts, Connecticut, Rhode Island, Vermont, New Hampshire, and Maine.

New York is the regional leader with approximately 20.0 million residents in 2025. Its dense healthcare infrastructure supports high volumes of hospital testing, pathology, infectious disease diagnostics, oncology, transplant testing, genetics, and reference-laboratory services. New York City also creates unusually high demand density for high-throughput laboratory systems.

Pennsylvania, with more than 13 million residents, provides a large mix of academic and community hospital demand. Philadelphia and Pittsburgh contain major medical centers and research institutions, creating a strong market for oncology, molecular, neurological, transplant, and specialized immunoassay consumables.

New Jersey combines a population exceeding 9.5 million with a significant pharmaceutical and life-sciences ecosystem. The state’s proximity to New York and Philadelphia also supports high diagnostic utilization and specialty laboratory operations.

Massachusetts has a smaller population base than New York or Pennsylvania but exerts disproportionate influence on diagnostic innovation. Boston’s academic hospitals, biotechnology companies, genomics organizations, and clinical research centers are important early-adoption sites for oncology biomarkers, neurological testing, transplant diagnostics, molecular assays, and precision medicine.

Maine, Vermont, and New Hampshire are smaller markets but have aging populations and rural-care requirements that increase the relevance of decentralized diagnostics. Cartridge-based systems that reduce dependence on centralized laboratory staffing are particularly attractive for geographically dispersed care systems.

The Northeast is projected to reach approximately USD 13.44 billion by 2035. Its growth rate will be somewhat lower than the West and South because population growth is slower, but high-test complexity, premium assay adoption, specialty medicine concentration, and strong reimbursement environments will preserve its value intensity.

Midwest

The Midwest represents an estimated USD 5.65 billion market in 2025 and is projected to reach approximately USD 10.64 billion by 2035. The region includes Illinois, Ohio, Michigan, Indiana, Wisconsin, Minnesota, Missouri, Iowa, Kansas, Nebraska, North Dakota, and South Dakota.

Illinois, Ohio, and Michigan form the largest population-based opportunities. Illinois had approximately 12.7 million residents in 2025, Ohio approximately 11.9 million, and Michigan more than 10.1 million. These states contain extensive hospital networks, cancer centers, academic laboratories, and community-health systems that support broad recurring consumable demand.

Chicago is a major laboratory market because of its population density and concentration of academic, pediatric, oncology, transplant, and integrated health-system infrastructure. Ohio has large specialty medical centers and a strong referral network, creating demand for molecular diagnostics, transplant assays, oncology testing, chemistry, microbiology, and hematology.

Minnesota is strategically influential because of its medical technology ecosystem, large integrated health systems, and sophisticated clinical laboratory infrastructure. Wisconsin and Indiana provide stable volumes in routine diagnostics while continuing to adopt automated and consolidated laboratory systems.

Missouri, Iowa, Kansas, Nebraska, North Dakota, and South Dakota include significant rural populations. In these markets, decentralized testing has particular value because rapid results can reduce dependence on distant reference laboratories. Cartridge-based molecular tests, point-of-care chemistry, and compact immunoassay platforms can therefore achieve meaningful clinical utility despite smaller absolute population bases.

The Midwest is unlikely to match the demographic growth rates of the South or West, but it remains a dependable market for high-volume chemistry, hematology, immunoassay, microbiology, diabetes, and hospital diagnostics. Manufacturers often compete successfully through dependable supply, strong field service, integrated health-system contracts, and demonstrable cost per reportable result.

Key Market Players

The U.S. IVD Consumables Competitive Landscape is moderately consolidated across core laboratory diagnostics but remains highly fragmented in specialty molecular, oncology, genomic, pathology, and point-of-care applications.

Competition is fundamentally installed-base driven. Companies that place high-throughput chemistry, immunoassay, molecular, hematology, coagulation, microbiology, or pathology systems can generate recurring reagent revenue for years. This makes new instrument placements strategically important even when instrument margins themselves are modest.

The competitive advantage increasingly depends on test-menu breadth, reagent reliability, proprietary cartridge design, manufacturing scale, FDA clearance, reimbursement support, quality-control integration, supply continuity, automation compatibility, and clinical evidence.

Some of the key players operating in the U.S. IVD consumables industry include:

Roche Diagnostics
Abbott Laboratories
Siemens Healthineers
Beckman Coulter Diagnostics, a Danaher company
Cepheid, a Danaher company
Thermo Fisher Scientific
Becton, Dickinson and Company
bioMérieux
QuidelOrtho
Hologic
QIAGEN
Bio-Rad Laboratories
Sysmex America
Werfen
DiaSorin
Fujirebio Diagnostics
Agilent Technologies
Illumina
Revvity
SEKISUI Diagnostics
Randox Laboratories
Trinity Biotech
Meridian Bioscience / SD Biosensor
ARKRAY

Roche, Abbott, Siemens Healthineers, Beckman Coulter, and other large core-laboratory suppliers possess strong competitive positions because they combine large analyzer footprints with broad recurring reagent menus. Their installed bases create high customer retention and support enterprise contracting with U.S. health systems.

Cepheid and bioMérieux are particularly influential in cartridge-based molecular and syndromic diagnostics, where rapid sample-to-answer workflows generate high recurring consumable value. Hologic and QIAGEN have strong positions in molecular and women’s health applications, while Bio-Rad participates across quality control, immunoassay, molecular, and laboratory reagents.

Sysmex and Werfen hold important positions in hematology, hemostasis, and specialty laboratory workflows. Fujirebio is becoming more strategically visible in neurological biomarkers, while Roche remains highly influential in tissue diagnostics and companion diagnostics.

Competition from specialized molecular and genomic companies will intensify through 2035. Large manufacturers may increasingly use partnerships, licensing, and acquisitions to add proprietary biomarkers to established analyzer platforms. Conversely, smaller diagnostic developers can create substantial value if they control clinically important intellectual property and secure reimbursement.

Market share will ultimately be determined by the ability to translate analytical innovation into routine clinical utilization. FDA authorization alone is insufficient. Manufacturers must secure laboratory validation, physician confidence, coding, payment, distribution, workflow integration, and reliable high-volume manufacturing before a novel assay becomes a material consumable revenue stream.

Recent Developments

The U.S. IVD consumables market has entered a new development cycle centered on decentralized molecular testing, blood-based biomarkers, companion diagnostics, and regulatory clarity.

In May 2025, the FDA cleared the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio, the first blood-based IVD cleared to aid diagnosis of Alzheimer’s disease. The test is intended for symptomatic adults aged 55 years and older and represents a significant development for specialty immunoassay consumables. Blood-based neurological testing has the potential to create a substantial new reagent category if biomarker testing becomes embedded in treatment-selection and patient-management pathways.

In 2024, bioMérieux received FDA clearance and CLIA-waived status for its BIOFIRE SPOTFIRE Respiratory/Sore Throat Panel. The multiplex PCR test can identify up to 15 respiratory and throat pathogens or subtypes in approximately 15 minutes. Further expansion of decentralized molecular testing supports recurring cartridge demand across urgent care centers, physician offices, emergency departments, and other near-patient environments.

Precision oncology continued to advance in 2025, with Roche receiving FDA Breakthrough Device Designation for a computational pathology companion diagnostic combining its VENTANA TROP2 immunohistochemistry assay with digital image analysis. The development reflects the direction of oncology consumables: reagent value is increasingly linked to treatment selection rather than diagnosis alone.

Abbott expanded its molecular assay menu during 2025 through FDA clearances and regulatory updates for the Alinity m platform, including viral testing applications such as BKV, CMV, hepatitis B, and hepatitis C. Menu expansion is commercially important because each new assay increases utilization of the same underlying automated molecular platform while generating additional proprietary reagent demand.

The regulatory environment surrounding laboratory-developed tests changed significantly. The FDA issued a final LDT rule in May 2024, but a federal district court vacated the rule in March 2025. In September 2025, FDA restored the regulatory definition to the text that existed before the 2024 rule. The outcome preserves a more complex competitive environment between manufacturer-developed IVDs and laboratory-developed testing than had been anticipated when the 2024 rule was issued.

Reimbursement policy is also evolving. Medicare’s Clinical Laboratory Fee Schedule continues to be linked to private payer data under PAMA. Legislative changes enacted in 2026 established a new data reporting period based on private payer information from the first half of 2025 and delayed additional CLFS payment reductions until 2027, when annual reductions for affected tests may be capped at 15% through 2029. This creates both visibility and continuing pricing pressure for laboratories and diagnostic manufacturers.

Conclusion

The U.S. IVD Consumables Market Size & Share is positioned to expand from approximately USD 31.20 billion in 2025 to USD 63.41 billion by 2035, representing a projected 7.35% CAGR during 2026–2035.

The long-term opportunity is supported by approximately 320,000 CLIA-regulated laboratory entities, a growing chronic disease population, repeated diagnostic monitoring requirements, expanding molecular testing, precision oncology, decentralized infectious disease testing, blood-based neurological biomarkers, and continued migration toward proprietary cartridge-based workflows.

The market should not be interpreted as a uniform commodity reagent category. Routine chemistry and hematology will continue to provide enormous recurring volume, but premium value growth will increasingly come from molecular cartridges, multiplex panels, oncology assays, companion diagnostics, specialty immunoassays, neurological biomarkers, transplant testing, high-sensitivity markers, and consumables that simplify technically complex laboratory procedures.

Hospital and laboratory procurement behavior will also become more economically disciplined. Buyers will increasingly assess consumables according to total cost per reportable result rather than reagent price alone. Labor savings, reagent waste, analyzer uptime, calibration frequency, turnaround time, test consolidation, clinical decision speed, and inventory requirements will materially influence vendor selection.

Regionally, the South will remain the largest U.S. market, supported by Texas, Florida, Georgia, North Carolina, Tennessee, Virginia, and other high-growth states. The West is positioned for the fastest expansion, driven by California’s innovation ecosystem and population growth in Arizona, Washington, Utah, Nevada, and Idaho. The Northeast will remain highly valuable for premium oncology, molecular, neurological, and academic testing, while the Midwest will provide a durable base of core laboratory and hospital demand.

For manufacturers, the most defensible strategy is to create an installed platform with a continuously expanding proprietary consumable menu. For laboratories, the key question is whether an assay improves clinical decision-making while fitting reimbursement and workflow economics. For investors and strategic buyers, the greatest value will be created by technologies that transform previously complex diagnostics into scalable, standardized, recurring-use consumables.

The U.S. IVD consumables market is therefore shifting from a reagent-volume business toward a recurring clinical-information business. Companies that control the consumable, the platform, the clinical evidence, and the workflow integration will be best positioned to capture the value created by the next decade of U.S. diagnostic testing.

TABLE OF CONTENT

1. U.S. IVD Consumables Market: Market Introduction & Context

1.1. Market Definition
1.2. Scope of the Study
1.3. Research Methodology
1.3.1. Primary Data Collection
1.3.2. Secondary Data Sourcing
1.3.3. External Industry Collaborations
1.3.4. In-House Research Databases
1.3.5. Analytical Frameworks & Forecasting Models
1.3.6. Data Validation and Final Report Publishing
1.4. Key Assumptions
1.5. Market Ecosystem Overview
1.6. Stakeholder Analysis
1.6.1. IVD Consumables and Reagent Manufacturers
1.6.2. Diagnostic Raw Material, Reagent Ingredient, and Component Suppliers
1.6.3. Contract Manufacturing, OEM, and Private-Label Partners
1.6.4. Hospitals, Health Systems, and Core Clinical Laboratories
1.6.5. Independent and National Reference Laboratories
1.6.6. Physician Offices, Urgent Care, Pharmacy, and Point-of-Care Testing Sites
1.6.7. Group Purchasing Organizations, Laboratory Distributors, and Specialty Suppliers
1.6.8. Payers, FDA, CMS, CLIA Authorities, and Laboratory Accreditation Organizations
What this section provides: This section defines the U.S. IVD consumables market boundary, product inclusion and exclusion criteria, research methodology, assumptions, and stakeholder ecosystem so clients understand how recurring diagnostic consumable revenue is measured and validated.

2. U.S. IVD Consumables Market: Executive Summary

2.1. Key Insights & Market Snapshot
2.2. Analyst Viewpoint
2.3. Market Attractiveness Index
2.4. Historical Market Summary, 2021–2024
2.5. Base Year Market Positioning, 2025
2.6. Forecast Outlook, 2026–2035
2.7. High-Growth Opportunity Areas
2.8. Recurring-Revenue and Installed-Base Economics Snapshot
2.9. Key Diagnostic Testing Demand Indicators
What this section provides: This section gives decision-makers a concise view of market size, historical normalization, forecast growth, recurring consumable economics, high-growth diagnostic categories, competitive intensity, and priority opportunity areas through 2035.

3. U.S. IVD Consumables Market: Market Dynamics & Outlook

3.1. Drivers and Their Impact Analysis
3.1.1. Rising Chronic Disease and Recurring Diagnostic Testing Burden
3.1.2. Expansion of Molecular Diagnostics and PCR Testing
3.1.3. Growth in Infectious Disease and Syndromic Testing
3.1.4. Expansion of Oncology Biomarkers and Companion Diagnostics
3.1.5. Growth of Point-of-Care and Decentralized Diagnostics
3.1.6. Increasing Laboratory Automation and Test-Menu Consolidation
3.1.7. Aging U.S. Population and Higher Testing Intensity
3.1.8. Expansion of Blood-Based and Minimally Invasive Diagnostics
3.2. Restraints and Their Impact Analysis
3.2.1. Clinical Laboratory Reimbursement and CLFS Pricing Pressure
3.2.2. Consumable Price Compression in Routine Testing Categories
3.2.3. Regulatory Compliance and Assay Validation Requirements
3.2.4. Supply-Chain Dependence on Specialty Chemicals, Antibodies, Enzymes, and Plastics
3.2.5. Laboratory Budget Constraints and Purchasing Consolidation
3.3. Opportunities and Their Impact Analysis
3.3.1. Multiplex and Syndromic Molecular Testing
3.3.2. Blood-Based Neurological Biomarkers
3.3.3. Precision Oncology and Companion Diagnostic Assays
3.3.4. CLIA-Waived Molecular and Near-Patient Testing
3.3.5. Home Testing and Remote Specimen Collection
3.3.6. High-Sensitivity Immunoassay Development
3.3.7. Reagent-Rental and Closed-Platform Consumable Models
3.4. Challenges and Their Impact Analysis
3.4.1. Laboratory Workforce Shortages
3.4.2. Assay Commoditization and Competitive Pricing
3.4.3. Reagent Lot Consistency and Quality-Control Complexity
3.4.4. Dependence on Installed Analyzer Platforms
3.4.5. Test Adoption, Coding, Coverage, and Payment Alignment
3.5. Patent & Innovation Analysis, 2021–2025
3.6. Clinical Laboratory Workflow Economics Analysis
3.7. Cost per Reportable Result Analysis
3.8. Reagent Utilization and Waste Economics
3.9. Analyzer Installed-Base and Consumable Pull-Through Analysis
3.10. Laboratory Procurement and Vendor Standardization Behavior Analysis
What this section provides: This section explains the clinical, commercial, reimbursement, regulatory, operational, and laboratory-economics forces influencing recurring IVD consumable demand and helps clients evaluate both growth opportunities and execution risks.

4. U.S. IVD Consumables Market: Market Environment & Industry Analysis

4.1. PESTEL Analysis
4.1.1. Political
4.1.2. Economic
4.1.3. Social
4.1.4. Technological
4.1.5. Environmental
4.1.6. Legal
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Laboratory and Health System Buyers
4.2.3. Bargaining Power of Raw Material and Component Suppliers
4.2.4. Substitution Risk
4.2.5. Competitive Rivalry
4.3. Pricing Trend Analysis by Region, 2025–2035
4.4. Value Chain & Supply Chain Analysis
4.4.1. Biological and Chemical Raw Material Suppliers
4.4.2. Antibody, Antigen, Enzyme, Primer, Probe, and Specialty Reagent Suppliers
4.4.3. Diagnostic Consumable Manufacturers
4.4.4. Cartridge, Cassette, Tube, and Medical-Grade Plastics Manufacturers
4.4.5. Distributors and Laboratory Supply Channels
4.4.6. Clinical Laboratories and Point-of-Care Testing Sites
4.5. Impact of Laboratory Automation and Digitalization
4.6. Application & Innovation Landscape
4.7. FDA IVD Regulatory Framework Analysis
4.8. Laboratory-Developed Test Regulatory Landscape
4.9. CLIA Compliance and Laboratory Complexity Framework
4.10. CMS Clinical Laboratory Fee Schedule and Reimbursement Landscape
4.11. PAMA and Private-Payer Data Impact Analysis
4.12. Import/Export Restrictions & Tariff Impact
4.13. Government Initiatives and Public Health Testing Programs
4.14. Impact of Escalating Geopolitical Tensions
4.15. Laboratory Value Analysis and Procurement Decision Framework
4.16. Reagent-Rental and Analyzer Placement Economics
What this section provides: This section gives clients a comprehensive view of the U.S. IVD operating environment, including regulation, reimbursement, CLIA requirements, laboratory economics, supply chains, pricing, automation, procurement models, and external market risks.

5. U.S. IVD Consumables Market – By Product Type

5.1. Overview
5.1.1. Segment Share Analysis, By Product Type, 2025 & 2035 (%)
5.2. Reagents and Assay Kits
5.2.1. Clinical Chemistry Reagents
5.2.2. Immunoassay Reagents
5.2.3. Molecular Diagnostic and PCR Reagents
5.2.4. Hematology and Coagulation Reagents
5.2.5. Microbiology Reagents
5.2.6. Histology, Cytology, and Tissue Diagnostic Reagents
5.3. Cartridges, Cassettes, Test Strips, and Single-Use Test Devices
5.3.1. Molecular Diagnostic Cartridges
5.3.2. Point-of-Care Test Cassettes
5.3.3. Blood Gas and Electrolyte Cartridges
5.3.4. Glucose and Metabolic Test Strips
5.3.5. Urinalysis Strips
5.3.6. Rapid Diagnostic Test Devices
5.4. Calibrators and Quality-Control Materials
5.4.1. Analyzer-Specific Calibrators
5.4.2. Multi-Analyte Controls
5.4.3. Third-Party Quality-Control Materials
5.4.4. Molecular Controls and Standards
5.4.5. Specialty Assay Controls
5.5. Sample Preparation and Extraction Consumables
5.5.1. Nucleic Acid Extraction Kits
5.5.2. Purification Columns and Magnetic Beads
5.5.3. Reaction Plates and Tubes
5.5.4. Pipette Tips and Liquid-Handling Consumables
5.5.5. Sample Processing and Preparation Kits
5.6. Specimen Collection, Transport, and Ancillary Consumables
5.6.1. Blood Collection Tubes
5.6.2. Swabs and Collection Devices
5.6.3. Specimen Containers
5.6.4. Transport Media
5.6.5. Lancets and Capillary Collection Devices
5.6.6. Sample Cups and Transfer Devices
What this section provides: This section identifies which recurring IVD consumable product categories are expected to generate the greatest revenue contribution, strongest recurring purchase frequency, and highest growth through 2035.

6. U.S. IVD Consumables Market – By Diagnostic Technology

6.1. Overview
6.1.1. Segment Share Analysis, By Diagnostic Technology, 2025 & 2035 (%)
6.2. Immunoassay
6.2.1. Chemiluminescence Immunoassay
6.2.2. Enzyme-Linked Immunosorbent Assay
6.2.3. Fluorescence Immunoassay
6.2.4. Lateral Flow Immunoassay
6.2.5. Other Immunoassay Technologies
6.3. Clinical Chemistry
6.3.1. General Chemistry
6.3.2. Electrolyte Testing
6.3.3. Enzyme Testing
6.3.4. Lipid and Metabolic Testing
6.3.5. Specialty Chemistry
6.4. Molecular Diagnostics and PCR
6.4.1. Real-Time PCR
6.4.2. Multiplex PCR
6.4.3. Digital PCR
6.4.4. Isothermal Amplification
6.4.5. Sequencing-Enabled Diagnostic Consumables
6.4.6. Other Nucleic Acid Amplification Technologies
6.5. Hematology and Coagulation
6.5.1. Hematology Reagents
6.5.2. Hemostasis and Coagulation Reagents
6.5.3. D-Dimer and Thrombosis Testing
6.5.4. Specialty Coagulation Testing
6.6. Microbiology
6.6.1. Culture Media
6.6.2. Blood Culture Consumables
6.6.3. Identification Reagents
6.6.4. Antimicrobial Susceptibility Testing Consumables
6.6.5. Rapid Microbiology Tests
6.7. Urinalysis and Other Specialized Diagnostics
6.7.1. Urinalysis
6.7.2. Histopathology and Immunohistochemistry
6.7.3. Autoimmune Diagnostics
6.7.4. Allergy Testing
6.7.5. Toxicology and Therapeutic Drug Monitoring
What this section provides: This section evaluates the diagnostic technologies driving consumable utilization and helps clients identify platforms where molecular testing, immunoassay innovation, automation, and specialty testing are increasing revenue per test.

7. U.S. IVD Consumables Market – By Application

7.1. Overview
7.1.1. Segment Share Analysis, By Application, 2025 & 2035 (%)
7.2. Infectious Diseases
7.2.1. Respiratory Infections
7.2.2. Sexually Transmitted Infections
7.2.3. Bloodstream Infections and Sepsis
7.2.4. Gastrointestinal Infections
7.2.5. HIV and Viral Hepatitis
7.2.6. Healthcare-Associated Infections
7.3. Diabetes and Metabolic Disorders
7.3.1. Glucose Testing
7.3.2. HbA1c Testing
7.3.3. Lipid and Metabolic Testing
7.3.4. Renal Complication Monitoring
7.3.5. Ketone and Acute Metabolic Testing
7.4. Oncology and Companion Diagnostics
7.4.1. Tumor Marker Testing
7.4.2. Immunohistochemistry
7.4.3. Molecular Oncology
7.4.4. Companion Diagnostics
7.4.5. Liquid Biopsy and Circulating Biomarkers
7.4.6. Treatment Response and Disease Monitoring
7.5. Cardiovascular and Critical Care
7.5.1. Cardiac Biomarkers
7.5.2. Coagulation and Thrombosis Testing
7.5.3. Blood Gas and Electrolyte Testing
7.5.4. Sepsis and Inflammatory Biomarkers
7.5.5. Emergency and Intensive Care Testing
7.6. Renal, Liver, and Other Chronic Disease Testing
7.6.1. Kidney Function Testing
7.6.2. Liver Function Testing
7.6.3. Thyroid and Endocrine Testing
7.6.4. Autoimmune Disease Testing
7.6.5. Chronic Disease Monitoring
7.7. Women’s Health, Genetic, and Reproductive Testing
7.7.1. Pregnancy Testing
7.7.2. HPV and Cervical Cancer Testing
7.7.3. Prenatal and Carrier Screening
7.7.4. Reproductive Hormone Testing
7.7.5. Genetic and Hereditary Disease Testing
What this section provides: This section helps clients understand consumable demand by clinical use case and prioritize disease areas where recurring testing, high-value biomarkers, precision medicine, and rapid diagnostics are expanding the addressable market.

8. U.S. IVD Consumables Market – By End User

8.1. Overview
8.1.1. Segment Share Analysis, By End User, 2025 & 2035 (%)
8.2. Hospitals and Hospital Laboratories
8.2.1. Academic Medical Centers
8.2.2. Integrated Delivery Networks
8.2.3. Community Hospitals
8.2.4. Emergency and Critical Care Laboratories
8.2.5. Hospital Point-of-Care Testing Programs
8.3. Independent and Reference Laboratories
8.3.1. National Reference Laboratories
8.3.2. Regional Independent Laboratories
8.3.3. Molecular and Genetic Laboratories
8.3.4. Pathology and Oncology Laboratories
8.4. Physician Offices, Urgent Care, and Near-Patient Testing Sites
8.4.1. Physician Office Laboratories
8.4.2. Urgent Care Centers
8.4.3. Community Clinics
8.4.4. Ambulatory Care Facilities
8.5. Retail, Pharmacy, and Home Testing
8.5.1. Retail Clinics
8.5.2. Pharmacy-Based Testing
8.5.3. Over-the-Counter Self-Testing
8.5.4. Home Specimen Collection
8.5.5. Direct-to-Consumer Testing Models
8.6. Public Health, Blood Banks, Academic, and Specialty Laboratories
8.6.1. Public Health Laboratories
8.6.2. Blood Banks and Transfusion Centers
8.6.3. Academic and Research Laboratories
8.6.4. Transplant Laboratories
8.6.5. Specialty Diagnostic Laboratories
What this section provides: This section identifies which laboratory and care settings are expected to drive recurring reagent consumption, premium assay adoption, decentralized testing, and high-volume diagnostic purchasing.

9. U.S. IVD Consumables Market – By Procurement Channel

9.1. Overview
9.1.1. Segment Share Analysis, By Procurement Channel, 2025 & 2035 (%)
9.2. Direct Manufacturer and Health System Contracts
9.2.1. Direct Hospital Laboratory Procurement
9.2.2. Enterprise Health System Agreements
9.2.3. National Reference Laboratory Agreements
9.3. Reagent-Rental and Analyzer Placement Agreements
9.3.1. Reagent-Rental Contracts
9.3.2. Instrument Placement Agreements
9.3.3. Cost-per-Test Agreements
9.3.4. Managed Laboratory Service Models
9.4. Group Purchasing Organization and IDN Contracts
9.4.1. GPO-Negotiated Consumable Contracts
9.4.2. IDN Vendor Standardization
9.4.3. Multi-Site Laboratory Agreements
9.5. Distributor and Specialty Laboratory Supplier Sales
9.5.1. National Medical Distributors
9.5.2. Specialty Diagnostic Distributors
9.5.3. Regional Laboratory Suppliers
9.6. Retail, Pharmacy, E-Commerce, and Direct-to-Consumer Channels
9.6.1. Pharmacy Distribution
9.6.2. Retail Distribution
9.6.3. E-Commerce
9.6.4. Direct-to-Consumer Channels
What this section provides: This section explains how IVD consumables are purchased across the United States, including direct contracts, reagent-rental models, IDN and GPO agreements, distributor channels, and emerging consumer-facing diagnostic procurement.

10. U.S. IVD Consumables Market – By Geography

10.1. Introduction
10.1.1. Segment Share Analysis, By Geography, 2025 & 2035 (%)
10.1.2. Regional Market Size and Forecast, 2021–2035 (US$ Billion)
10.1.3. Regional Laboratory Infrastructure and Diagnostic Test Volume Analysis
10.1.4. Regional Chronic Disease and Infectious Disease Testing Demand
10.1.5. Regional Reimbursement and Procurement Dynamics
10.1.6. Regional Point-of-Care and Molecular Diagnostic Adoption Analysis

10.2. West Region
10.2.1. Regional Overview & Trends
10.2.2. West Region IVD Consumables Key Manufacturers, Laboratories, and Procurement Ecosystem
10.2.3. West Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.2.4. West Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.5. West Region Market Size and Forecast, By Diagnostic Technology, 2021–2035 (US$ Billion)
10.2.6. West Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.7. West Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.8. West Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.9. California
10.2.9.1. Overview
10.2.9.2. California Market Size and Forecast, By Product Type, 2021–2035
10.2.9.3. California Market Size and Forecast, By Diagnostic Technology, 2021–2035
10.2.9.4. California Market Size and Forecast, By Application, 2021–2035
10.2.9.5. California Market Size and Forecast, By End User, 2021–2035
10.2.9.6. California Market Size and Forecast, By Procurement Channel, 2021–2035
10.2.10. Washington
10.2.10.1. Overview
10.2.10.2. Washington Market Size and Forecast, By Product Type, 2021–2035
10.2.10.3. Washington Market Size and Forecast, By Diagnostic Technology, 2021–2035
10.2.10.4. Washington Market Size and Forecast, By Application, 2021–2035
10.2.10.5. Washington Market Size and Forecast, By End User, 2021–2035
10.2.10.6. Washington Market Size and Forecast, By Procurement Channel, 2021–2035
10.2.11. Arizona
10.2.11.1. Overview
10.2.11.2. Arizona Market Size and Forecast, By Product Type, 2021–2035
10.2.11.3. Arizona Market Size and Forecast, By Diagnostic Technology, 2021–2035
10.2.11.4. Arizona Market Size and Forecast, By Application, 2021–2035
10.2.11.5. Arizona Market Size and Forecast, By End User, 2021–2035
10.2.11.6. Arizona Market Size and Forecast, By Procurement Channel, 2021–2035
10.2.12. Colorado
10.2.12.1. Overview
10.2.12.2. Colorado Market Size and Forecast, By Product Type, 2021–2035
10.2.12.3. Colorado Market Size and Forecast, By Diagnostic Technology, 2021–2035
10.2.12.4. Colorado Market Size and Forecast, By Application, 2021–2035
10.2.12.5. Colorado Market Size and Forecast, By End User, 2021–2035
10.2.12.6. Colorado Market Size and Forecast, By Procurement Channel, 2021–2035
10.2.13. Oregon
10.2.13.1. Overview
10.2.13.2. Oregon Market Size and Forecast, By Product Type, 2021–2035
10.2.13.3. Oregon Market Size and Forecast, By Diagnostic Technology, 2021–2035
10.2.13.4. Oregon Market Size and Forecast, By Application, 2021–2035
10.2.13.5. Oregon Market Size and Forecast, By End User, 2021–2035
10.2.13.6. Oregon Market Size and Forecast, By Procurement Channel, 2021–2035
10.2.14. Utah
10.2.14.1. Overview
10.2.14.2. Utah Market Size and Forecast, By Product Type, 2021–2035
10.2.14.3. Utah Market Size and Forecast, By Diagnostic Technology, 2021–2035
10.2.14.4. Utah Market Size and Forecast, By Application, 2021–2035
10.2.14.5. Utah Market Size and Forecast, By End User, 2021–2035
10.2.14.6. Utah Market Size and Forecast, By Procurement Channel, 2021–2035
10.2.15. Nevada
10.2.15.1. Overview
10.2.15.2. Nevada Market Size and Forecast, By Product Type, 2021–2035
10.2.15.3. Nevada Market Size and Forecast, By Diagnostic Technology, 2021–2035
10.2.15.4. Nevada Market Size and Forecast, By Application, 2021–2035
10.2.15.5. Nevada Market Size and Forecast, By End User, 2021–2035
10.2.15.6. Nevada Market Size and Forecast, By Procurement Channel, 2021–2035
10.2.16. New Mexico
10.2.16.1. Overview
10.2.16.2. New Mexico Market Size and Forecast, By Product Type, 2021–2035
10.2.16.3. New Mexico Market Size and Forecast, By Diagnostic Technology, 2021–2035
10.2.16.4. New Mexico Market Size and Forecast, By Application, 2021–2035
10.2.16.5. New Mexico Market Size and Forecast, By End User, 2021–2035
10.2.16.6. New Mexico Market Size and Forecast, By Procurement Channel, 2021–2035
10.2.17. Idaho
10.2.17.1. Overview
10.2.17.2. Idaho Market Size and Forecast, By Product Type, 2021–2035
10.2.17.3. Idaho Market Size and Forecast, By Diagnostic Technology, 2021–2035
10.2.17.4. Idaho Market Size and Forecast, By Application, 2021–2035
10.2.17.5. Idaho Market Size and Forecast, By End User, 2021–2035
10.2.17.6. Idaho Market Size and Forecast, By Procurement Channel, 2021–2035
10.2.18. Montana
10.2.18.1. Overview
10.2.18.2. Montana Market Size and Forecast, By Product Type, 2021–2035
10.2.18.3. Montana Market Size and Forecast, By Diagnostic Technology, 2021–2035
10.2.18.4. Montana Market Size and Forecast, By Application, 2021–2035
10.2.18.5. Montana Market Size and Forecast, By End User, 2021–2035
10.2.18.6. Montana Market Size and Forecast, By Procurement Channel, 2021–2035
10.2.19. Wyoming
10.2.19.1. Overview
10.2.19.2. Wyoming Market Size and Forecast, By Product Type, 2021–2035
10.2.19.3. Wyoming Market Size and Forecast, By Diagnostic Technology, 2021–2035
10.2.19.4. Wyoming Market Size and Forecast, By Application, 2021–2035
10.2.19.5. Wyoming Market Size and Forecast, By End User, 2021–2035
10.2.19.6. Wyoming Market Size and Forecast, By Procurement Channel, 2021–2035
10.2.20. Alaska
10.2.20.1. Overview
10.2.20.2. Alaska Market Size and Forecast, By Product Type, 2021–2035
10.2.20.3. Alaska Market Size and Forecast, By Diagnostic Technology, 2021–2035
10.2.20.4. Alaska Market Size and Forecast, By Application, 2021–2035
10.2.20.5. Alaska Market Size and Forecast, By End User, 2021–2035
10.2.20.6. Alaska Market Size and Forecast, By Procurement Channel, 2021–2035
10.2.21. Hawaii
10.2.21.1. Overview
10.2.21.2. Hawaii Market Size and Forecast, By Product Type, 2021–2035
10.2.21.3. Hawaii Market Size and Forecast, By Diagnostic Technology, 2021–2035
10.2.21.4. Hawaii Market Size and Forecast, By Application, 2021–2035
10.2.21.5. Hawaii Market Size and Forecast, By End User, 2021–2035
10.2.21.6. Hawaii Market Size and Forecast, By Procurement Channel, 2021–2035

10.3. Northeast Region
10.3.1. Regional Overview & Trends
10.3.2. Northeast Region IVD Consumables Key Manufacturers, Laboratories, and Procurement Ecosystem
10.3.3. Northeast Region Market Size and Forecast, By State, 2021–2035
10.3.4. Northeast Region Market Size and Forecast, By Product Type, 2021–2035
10.3.5. Northeast Region Market Size and Forecast, By Diagnostic Technology, 2021–2035
10.3.6. Northeast Region Market Size and Forecast, By Application, 2021–2035
10.3.7. Northeast Region Market Size and Forecast, By End User, 2021–2035
10.3.8. Northeast Region Market Size and Forecast, By Procurement Channel, 2021–2035
10.3.9. New York
10.3.9.1. Overview
10.3.9.2. New York Market Size and Forecast, By Product Type, 2021–2035
10.3.9.3. New York Market Size and Forecast, By Diagnostic Technology, 2021–2035
10.3.9.4. New York Market Size and Forecast, By Application, 2021–2035
10.3.9.5. New York Market Size and Forecast, By End User, 2021–2035
10.3.9.6. New York Market Size and Forecast, By Procurement Channel, 2021–2035
10.3.10. Massachusetts
10.3.10.1. Overview
10.3.10.2. Massachusetts Market Size and Forecast, By Product Type, 2021–2035
10.3.10.3. Massachusetts Market Size and Forecast, By Diagnostic Technology, 2021–2035
10.3.10.4. Massachusetts Market Size and Forecast, By Application, 2021–2035
10.3.10.5. Massachusetts Market Size and Forecast, By End User, 2021–2035
10.3.10.6. Massachusetts Market Size and Forecast, By Procurement Channel, 2021–2035
10.3.11. New Jersey
10.3.11.1. Overview
10.3.11.2. New Jersey Market Size and Forecast, By Product Type, 2021–2035
10.3.11.3. New Jersey Market Size and Forecast, By Diagnostic Technology, 2021–2035
10.3.11.4. New Jersey Market Size and Forecast, By Application, 2021–2035
10.3.11.5. New Jersey Market Size and Forecast, By End User, 2021–2035
10.3.11.6. New Jersey Market Size and Forecast, By Procurement Channel, 2021–2035
10.3.12. Pennsylvania
10.3.12.1. Overview
10.3.12.2. Pennsylvania Market Size and Forecast, By Product Type, 2021–2035
10.3.12.3. Pennsylvania Market Size and Forecast, By Diagnostic Technology, 2021–2035
10.3.12.4. Pennsylvania Market Size and Forecast, By Application, 2021–2035
10.3.12.5. Pennsylvania Market Size and Forecast, By End User, 2021–2035
10.3.12.6. Pennsylvania Market Size and Forecast, By Procurement Channel, 2021–2035
10.3.13. Connecticut
10.3.13.1. Overview
10.3.13.2. Connecticut Market Size and Forecast, By Product Type, 2021–2035
10.3.13.3. Connecticut Market Size and Forecast, By Diagnostic Technology, 2021–2035
10.3.13.4. Connecticut Market Size and Forecast, By Application, 2021–2035
10.3.13.5. Connecticut Market Size and Forecast, By End User, 2021–2035
10.3.13.6. Connecticut Market Size and Forecast, By Procurement Channel, 2021–2035
10.3.14. Maine
10.3.14.1. Overview
10.3.14.2. Maine Market Size and Forecast, By Product Type, 2021–2035
10.3.14.3. Maine Market Size and Forecast, By Diagnostic Technology, 2021–2035
10.3.14.4. Maine Market Size and Forecast, By Application, 2021–2035
10.3.14.5. Maine Market Size and Forecast, By End User, 2021–2035
10.3.14.6. Maine Market Size and Forecast, By Procurement Channel, 2021–2035
10.3.15. Vermont
10.3.15.1. Overview
10.3.15.2. Vermont Market Size and Forecast, By Product Type, 2021–2035
10.3.15.3. Vermont Market Size and Forecast, By Diagnostic Technology, 2021–2035
10.3.15.4. Vermont Market Size and Forecast, By Application, 2021–2035
10.3.15.5. Vermont Market Size and Forecast, By End User, 2021–2035
10.3.15.6. Vermont Market Size and Forecast, By Procurement Channel, 2021–2035
10.3.16. New Hampshire
10.3.16.1. Overview
10.3.16.2. New Hampshire Market Size and Forecast, By Product Type, 2021–2035
10.3.16.3. New Hampshire Market Size and Forecast, By Diagnostic Technology, 2021–2035
10.3.16.4. New Hampshire Market Size and Forecast, By Application, 2021–2035
10.3.16.5. New Hampshire Market Size and Forecast, By End User, 2021–2035
10.3.16.6. New Hampshire Market Size and Forecast, By Procurement Channel, 2021–2035
10.3.17. Rhode Island
10.3.17.1. Overview
10.3.17.2. Rhode Island Market Size and Forecast, By Product Type, 2021–2035
10.3.17.3. Rhode Island Market Size and Forecast, By Diagnostic Technology, 2021–2035
10.3.17.4. Rhode Island Market Size and Forecast, By Application, 2021–2035
10.3.17.5. Rhode Island Market Size and Forecast, By End User, 2021–2035
10.3.17.6. Rhode Island Market Size and Forecast, By Procurement Channel, 2021–2035
10.3.18. Delaware
10.3.18.1. Overview
10.3.18.2. Delaware Market Size and Forecast, By Product Type, 2021–2035
10.3.18.3. Delaware Market Size and Forecast, By Diagnostic Technology, 2021–2035
10.3.18.4. Delaware Market Size and Forecast, By Application, 2021–2035
10.3.18.5. Delaware Market Size and Forecast, By End User, 2021–2035
10.3.18.6. Delaware Market Size and Forecast, By Procurement Channel, 2021–2035

10.4. South Region
10.4.1. Regional Overview & Trends
10.4.2. South Region IVD Consumables Key Manufacturers, Laboratories, and Procurement Ecosystem
10.4.3. South Region Market Size and Forecast, By State, 2021–2035
10.4.4. South Region Market Size and Forecast, By Product Type, 2021–2035
10.4.5. South Region Market Size and Forecast, By Diagnostic Technology, 2021–2035
10.4.6. South Region Market Size and Forecast, By Application, 2021–2035
10.4.7. South Region Market Size and Forecast, By End User, 2021–2035
10.4.8. South Region Market Size and Forecast, By Procurement Channel, 2021–2035
10.4.9. Texas
10.4.9.1. Overview
10.4.9.2. Texas Market Size and Forecast, By Product Type, 2021–2035
10.4.9.3. Texas Market Size and Forecast, By Diagnostic Technology, 2021–2035
10.4.9.4. Texas Market Size and Forecast, By Application, 2021–2035
10.4.9.5. Texas Market Size and Forecast, By End User, 2021–2035
10.4.9.6. Texas Market Size and Forecast, By Procurement Channel, 2021–2035
10.4.10. Florida
10.4.10.1. Overview
10.4.10.2. Florida Market Size and Forecast, By Product Type, 2021–2035
10.4.10.3. Florida Market Size and Forecast, By Diagnostic Technology, 2021–2035
10.4.10.4. Florida Market Size and Forecast, By Application, 2021–2035
10.4.10.5. Florida Market Size and Forecast, By End User, 2021–2035
10.4.10.6. Florida Market Size and Forecast, By Procurement Channel, 2021–2035
10.4.11. Georgia
10.4.11.1. Overview
10.4.11.2. Georgia Market Size and Forecast, By Product Type, 2021–2035
10.4.11.3. Georgia Market Size and Forecast, By Diagnostic Technology, 2021–2035
10.4.11.4. Georgia Market Size and Forecast, By Application, 2021–2035
10.4.11.5. Georgia Market Size and Forecast, By End User, 2021–2035
10.4.11.6. Georgia Market Size and Forecast, By Procurement Channel, 2021–2035
10.4.12. North Carolina
10.4.12.1. Overview
10.4.12.2. North Carolina Market Size and Forecast, By Product Type, 2021–2035
10.4.12.3. North Carolina Market Size and Forecast, By Diagnostic Technology, 2021–2035
10.4.12.4. North Carolina Market Size and Forecast, By Application, 2021–2035
10.4.12.5. North Carolina Market Size and Forecast, By End User, 2021–2035
10.4.12.6. North Carolina Market Size and Forecast, By Procurement Channel, 2021–2035
10.4.13. Tennessee
10.4.13.1. Overview
10.4.13.2. Tennessee Market Size and Forecast, By Product Type, 2021–2035
10.4.13.3. Tennessee Market Size and Forecast, By Diagnostic Technology, 2021–2035
10.4.13.4. Tennessee Market Size and Forecast, By Application, 2021–2035
10.4.13.5. Tennessee Market Size and Forecast, By End User, 2021–2035
10.4.13.6. Tennessee Market Size and Forecast, By Procurement Channel, 2021–2035
10.4.14. South Carolina
10.4.14.1. Overview
10.4.14.2. South Carolina Market Size and Forecast, By Product Type, 2021–2035
10.4.14.3. South Carolina Market Size and Forecast, By Diagnostic Technology, 2021–2035
10.4.14.4. South Carolina Market Size and Forecast, By Application, 2021–2035
10.4.14.5. South Carolina Market Size and Forecast, By End User, 2021–2035
10.4.14.6. South Carolina Market Size and Forecast, By Procurement Channel, 2021–2035
10.4.15. Alabama
10.4.15.1. Overview
10.4.15.2. Alabama Market Size and Forecast, By Product Type, 2021–2035
10.4.15.3. Alabama Market Size and Forecast, By Diagnostic Technology, 2021–2035
10.4.15.4. Alabama Market Size and Forecast, By Application, 2021–2035
10.4.15.5. Alabama Market Size and Forecast, By End User, 2021–2035
10.4.15.6. Alabama Market Size and Forecast, By Procurement Channel, 2021–2035
10.4.16. Mississippi
10.4.16.1. Overview
10.4.16.2. Mississippi Market Size and Forecast, By Product Type, 2021–2035
10.4.16.3. Mississippi Market Size and Forecast, By Diagnostic Technology, 2021–2035
10.4.16.4. Mississippi Market Size and Forecast, By Application, 2021–2035
10.4.16.5. Mississippi Market Size and Forecast, By End User, 2021–2035
10.4.16.6. Mississippi Market Size and Forecast, By Procurement Channel, 2021–2035
10.4.17. Louisiana
10.4.17.1. Overview
10.4.17.2. Louisiana Market Size and Forecast, By Product Type, 2021–2035
10.4.17.3. Louisiana Market Size and Forecast, By Diagnostic Technology, 2021–2035
10.4.17.4. Louisiana Market Size and Forecast, By Application, 2021–2035
10.4.17.5. Louisiana Market Size and Forecast, By End User, 2021–2035
10.4.17.6. Louisiana Market Size and Forecast, By Procurement Channel, 2021–2035
10.4.18. Arkansas
10.4.18.1. Overview
10.4.18.2. Arkansas Market Size and Forecast, By Product Type, 2021–2035
10.4.18.3. Arkansas Market Size and Forecast, By Diagnostic Technology, 2021–2035
10.4.18.4. Arkansas Market Size and Forecast, By Application, 2021–2035
10.4.18.5. Arkansas Market Size and Forecast, By End User, 2021–2035
10.4.18.6. Arkansas Market Size and Forecast, By Procurement Channel, 2021–2035
10.4.19. Kentucky
10.4.19.1. Overview
10.4.19.2. Kentucky Market Size and Forecast, By Product Type, 2021–2035
10.4.19.3. Kentucky Market Size and Forecast, By Diagnostic Technology, 2021–2035
10.4.19.4. Kentucky Market Size and Forecast, By Application, 2021–2035
10.4.19.5. Kentucky Market Size and Forecast, By End User, 2021–2035
10.4.19.6. Kentucky Market Size and Forecast, By Procurement Channel, 2021–2035
10.4.20. Oklahoma
10.4.20.1. Overview
10.4.20.2. Oklahoma Market Size and Forecast, By Product Type, 2021–2035
10.4.20.3. Oklahoma Market Size and Forecast, By Diagnostic Technology, 2021–2035
10.4.20.4. Oklahoma Market Size and Forecast, By Application, 2021–2035
10.4.20.5. Oklahoma Market Size and Forecast, By End User, 2021–2035
10.4.20.6. Oklahoma Market Size and Forecast, By Procurement Channel, 2021–2035
10.4.21. Virginia
10.4.21.1. Overview
10.4.21.2. Virginia Market Size and Forecast, By Product Type, 2021–2035
10.4.21.3. Virginia Market Size and Forecast, By Diagnostic Technology, 2021–2035
10.4.21.4. Virginia Market Size and Forecast, By Application, 2021–2035
10.4.21.5. Virginia Market Size and Forecast, By End User, 2021–2035
10.4.21.6. Virginia Market Size and Forecast, By Procurement Channel, 2021–2035
10.4.22. Maryland
10.4.22.1. Overview
10.4.22.2. Maryland Market Size and Forecast, By Product Type, 2021–2035
10.4.22.3. Maryland Market Size and Forecast, By Diagnostic Technology, 2021–2035
10.4.22.4. Maryland Market Size and Forecast, By Application, 2021–2035
10.4.22.5. Maryland Market Size and Forecast, By End User, 2021–2035
10.4.22.6. Maryland Market Size and Forecast, By Procurement Channel, 2021–2035
10.4.23. West Virginia
10.4.23.1. Overview
10.4.23.2. West Virginia Market Size and Forecast, By Product Type, 2021–2035
10.4.23.3. West Virginia Market Size and Forecast, By Diagnostic Technology, 2021–2035
10.4.23.4. West Virginia Market Size and Forecast, By Application, 2021–2035
10.4.23.5. West Virginia Market Size and Forecast, By End User, 2021–2035
10.4.23.6. West Virginia Market Size and Forecast, By Procurement Channel, 2021–2035

10.5. Midwest Region
10.5.1. Regional Overview & Trends
10.5.2. Midwest Region IVD Consumables Key Manufacturers, Laboratories, and Procurement Ecosystem
10.5.3. Midwest Region Market Size and Forecast, By State, 2021–2035
10.5.4. Midwest Region Market Size and Forecast, By Product Type, 2021–2035
10.5.5. Midwest Region Market Size and Forecast, By Diagnostic Technology, 2021–2035
10.5.6. Midwest Region Market Size and Forecast, By Application, 2021–2035
10.5.7. Midwest Region Market Size and Forecast, By End User, 2021–2035
10.5.8. Midwest Region Market Size and Forecast, By Procurement Channel, 2021–2035
10.5.9. Illinois
10.5.9.1. Overview
10.5.9.2. Illinois Market Size and Forecast, By Product Type, 2021–2035
10.5.9.3. Illinois Market Size and Forecast, By Diagnostic Technology, 2021–2035
10.5.9.4. Illinois Market Size and Forecast, By Application, 2021–2035
10.5.9.5. Illinois Market Size and Forecast, By End User, 2021–2035
10.5.9.6. Illinois Market Size and Forecast, By Procurement Channel, 2021–2035
10.5.10. Ohio
10.5.10.1. Overview
10.5.10.2. Ohio Market Size and Forecast, By Product Type, 2021–2035
10.5.10.3. Ohio Market Size and Forecast, By Diagnostic Technology, 2021–2035
10.5.10.4. Ohio Market Size and Forecast, By Application, 2021–2035
10.5.10.5. Ohio Market Size and Forecast, By End User, 2021–2035
10.5.10.6. Ohio Market Size and Forecast, By Procurement Channel, 2021–2035
10.5.11. Michigan
10.5.11.1. Overview
10.5.11.2. Michigan Market Size and Forecast, By Product Type, 2021–2035
10.5.11.3. Michigan Market Size and Forecast, By Diagnostic Technology, 2021–2035
10.5.11.4. Michigan Market Size and Forecast, By Application, 2021–2035
10.5.11.5. Michigan Market Size and Forecast, By End User, 2021–2035
10.5.11.6. Michigan Market Size and Forecast, By Procurement Channel, 2021–2035
10.5.12. Minnesota
10.5.12.1. Overview
10.5.12.2. Minnesota Market Size and Forecast, By Product Type, 2021–2035
10.5.12.3. Minnesota Market Size and Forecast, By Diagnostic Technology, 2021–2035
10.5.12.4. Minnesota Market Size and Forecast, By Application, 2021–2035
10.5.12.5. Minnesota Market Size and Forecast, By End User, 2021–2035
10.5.12.6. Minnesota Market Size and Forecast, By Procurement Channel, 2021–2035
10.5.13. Indiana
10.5.13.1. Overview
10.5.13.2. Indiana Market Size and Forecast, By Product Type, 2021–2035
10.5.13.3. Indiana Market Size and Forecast, By Diagnostic Technology, 2021–2035
10.5.13.4. Indiana Market Size and Forecast, By Application, 2021–2035
10.5.13.5. Indiana Market Size and Forecast, By End User, 2021–2035
10.5.13.6. Indiana Market Size and Forecast, By Procurement Channel, 2021–2035
10.5.14. Wisconsin
10.5.14.1. Overview
10.5.14.2. Wisconsin Market Size and Forecast, By Product Type, 2021–2035
10.5.14.3. Wisconsin Market Size and Forecast, By Diagnostic Technology, 2021–2035
10.5.14.4. Wisconsin Market Size and Forecast, By Application, 2021–2035
10.5.14.5. Wisconsin Market Size and Forecast, By End User, 2021–2035
10.5.14.6. Wisconsin Market Size and Forecast, By Procurement Channel, 2021–2035
10.5.15. Missouri
10.5.15.1. Overview
10.5.15.2. Missouri Market Size and Forecast, By Product Type, 2021–2035
10.5.15.3. Missouri Market Size and Forecast, By Diagnostic Technology, 2021–2035
10.5.15.4. Missouri Market Size and Forecast, By Application, 2021–2035
10.5.15.5. Missouri Market Size and Forecast, By End User, 2021–2035
10.5.15.6. Missouri Market Size and Forecast, By Procurement Channel, 2021–2035
10.5.16. Iowa
10.5.16.1. Overview
10.5.16.2. Iowa Market Size and Forecast, By Product Type, 2021–2035
10.5.16.3. Iowa Market Size and Forecast, By Diagnostic Technology, 2021–2035
10.5.16.4. Iowa Market Size and Forecast, By Application, 2021–2035
10.5.16.5. Iowa Market Size and Forecast, By End User, 2021–2035
10.5.16.6. Iowa Market Size and Forecast, By Procurement Channel, 2021–2035
10.5.17. Kansas
10.5.17.1. Overview
10.5.17.2. Kansas Market Size and Forecast, By Product Type, 2021–2035
10.5.17.3. Kansas Market Size and Forecast, By Diagnostic Technology, 2021–2035
10.5.17.4. Kansas Market Size and Forecast, By Application, 2021–2035
10.5.17.5. Kansas Market Size and Forecast, By End User, 2021–2035
10.5.17.6. Kansas Market Size and Forecast, By Procurement Channel, 2021–2035
10.5.18. Nebraska
10.5.18.1. Overview
10.5.18.2. Nebraska Market Size and Forecast, By Product Type, 2021–2035
10.5.18.3. Nebraska Market Size and Forecast, By Diagnostic Technology, 2021–2035
10.5.18.4. Nebraska Market Size and Forecast, By Application, 2021–2035
10.5.18.5. Nebraska Market Size and Forecast, By End User, 2021–2035
10.5.18.6. Nebraska Market Size and Forecast, By Procurement Channel, 2021–2035
10.5.19. North Dakota
10.5.19.1. Overview
10.5.19.2. North Dakota Market Size and Forecast, By Product Type, 2021–2035
10.5.19.3. North Dakota Market Size and Forecast, By Diagnostic Technology, 2021–2035
10.5.19.4. North Dakota Market Size and Forecast, By Application, 2021–2035
10.5.19.5. North Dakota Market Size and Forecast, By End User, 2021–2035
10.5.19.6. North Dakota Market Size and Forecast, By Procurement Channel, 2021–2035
10.5.20. South Dakota
10.5.20.1. Overview
10.5.20.2. South Dakota Market Size and Forecast, By Product Type, 2021–2035
10.5.20.3. South Dakota Market Size and Forecast, By Diagnostic Technology, 2021–2035
10.5.20.4. South Dakota Market Size and Forecast, By Application, 2021–2035
10.5.20.5. South Dakota Market Size and Forecast, By End User, 2021–2035
10.5.20.6. South Dakota Market Size and Forecast, By Procurement Channel, 2021–2035
What this section provides: This section delivers detailed four-region and all-50-state analysis, enabling clients to identify major laboratory markets, diagnostic testing hubs, population-growth opportunities, disease-driven consumable demand, decentralized testing hotspots, and state-level commercial priorities.

11. U.S. IVD Consumables Market: Competitive Landscape & Company Profiles

11.1. Market Share Analysis, 2025
11.2. Competitive Benchmarking by Consumable Portfolio
11.3. Company Positioning Matrix
11.3.1. Leaders
11.3.2. Challengers
11.3.3. Innovators
11.3.4. Emerging and Specialized Players
11.4. Installed Analyzer Base and Reagent Pull-Through Analysis
11.5. Competitive Pricing and Contracting Analysis
11.6. Strategic Partnership, Licensing, and Acquisition Landscape
11.7. Company Profiles
11.7.1. Roche Diagnostics
11.7.2. Abbott Laboratories
11.7.3. Siemens Healthineers
11.7.4. Beckman Coulter Diagnostics
11.7.5. Cepheid
11.7.6. Thermo Fisher Scientific
11.7.7. Becton, Dickinson and Company
11.7.8. bioMérieux
11.7.9. QuidelOrtho
11.7.10. Hologic
11.7.11. QIAGEN
11.7.12. Bio-Rad Laboratories
11.7.13. Sysmex America
11.7.14. Werfen
11.7.15. DiaSorin
11.7.16. Fujirebio Diagnostics
11.7.17. Agilent Technologies
11.7.18. Illumina
11.7.19. Revvity
11.7.20. SEKISUI Diagnostics
11.7.21. Randox Laboratories
11.7.22. Trinity Biotech
11.7.23. Meridian Bioscience / SD Biosensor
11.7.24. ARKRAY
11.7.25. Sekisui Medical / Specialty Diagnostic Operations
Note: Each company profile will include company overview, U.S. IVD consumables portfolio, key reagent and assay platforms, installed-base strategy, U.S. commercial positioning, financial positioning where applicable, pipeline and test-menu expansion, FDA regulatory updates, partnerships, acquisitions, and recent developments.
What this section provides: This section gives clients competitor benchmarking, market-share visibility, installed-base positioning, reagent portfolio intelligence, molecular and specialty diagnostic capabilities, innovation direction, contracting strategy, and strategic intelligence on major U.S. IVD consumables suppliers.

12. U.S. IVD Consumables Market: Future Market Outlook, 2026–2035

12.1. Scenario Analysis
12.1.1. Optimistic Scenario
12.1.2. Realistic Scenario
12.1.3. Pessimistic Scenario
12.2. Disruptive Technologies Impact
12.2.1. Multiplex and Syndromic Molecular Cartridges
12.2.2. Blood-Based Neurological Biomarkers
12.2.3. Liquid Biopsy and Circulating Tumor Biomarkers
12.2.4. Digital PCR and High-Sensitivity Molecular Testing
12.2.5. Next-Generation Companion Diagnostics
12.2.6. Automated Sample-to-Answer Diagnostic Cartridges
12.2.7. At-Home and Connected Diagnostic Testing
12.2.8. AI-Assisted Pathology and Quantitative Biomarker Interpretation
12.3. Emerging Business Trends
12.3.1. Shift from Commodity Reagents to High-Value Proprietary Assays
12.3.2. Test-Menu Expansion on Existing Analyzer Platforms
12.3.3. Laboratory Consolidation and Enterprise Vendor Standardization
12.3.4. Growth of Reagent-Rental Commercial Models
12.3.5. Increasing Demand for Low-Labor Diagnostic Workflows
12.4. Business Opportunities for Startups and Existing Players
12.5. Investment Prioritization Matrix
12.6. High-Growth Assay Opportunity Matrix
12.7. Market White-Space Analysis
12.8. Potential Market Disruption Risks Through 2035
What this section provides: This section prepares clients for future technology shifts, assay innovation, diagnostic decentralization, changing laboratory economics, competitive disruption, investment opportunities, and potential market-development scenarios through 2035.

13. U.S. IVD Consumables Market: Strategic Recommendations

13.1. Recommendations for IVD Consumables Manufacturers
13.2. Recommendations for Hospitals, Health Systems, and Clinical Laboratories
13.3. Recommendations for Independent and Reference Laboratories
13.4. Recommendations for Investors and Private Equity Firms
13.5. Recommendations for Distributors and Channel Partners
13.6. Recommendations for New Entrants and Diagnostic Startups
13.7. Go-to-Market Strategy Considerations
13.8. Product Positioning and Test-Menu Expansion Guidance
13.9. Analyzer Installed-Base Expansion Strategy
13.10. Reagent-Rental and Cost-per-Test Contracting Strategy
13.11. FDA, Reimbursement, and Market-Access Strategy
13.12. State and Regional Commercial Prioritization Strategy
What this section provides: This section converts market intelligence into actionable recommendations for assay development, portfolio expansion, installed-base growth, pricing, contracting, reimbursement, distribution, geographic prioritization, and competitive differentiation.

14. U.S. IVD Consumables Market: Disclaimer

14.1. Scope Limitation
14.2. Data Use Limitation
14.3. Market Sizing and Forecasting Limitation
14.4. Clinical and Regulatory Information Limitation
14.5. Legal Disclaimer
14.6. Third-Party Data Disclaimer
What this section provides: This section clarifies the report’s market-scope boundaries, methodological limitations, forecasting assumptions, regulatory-data limitations, legal conditions, and third-party data-use considerations.

List of Tables

TABLE 1: List of Data Sources
TABLE 2: U.S. IVD Consumables Market: Market Definition and Scope
TABLE 3: U.S. IVD Consumables Market: Research Methodology Framework
TABLE 4: U.S. IVD Consumables Market: Key Assumptions
TABLE 5: U.S. IVD Consumables Market: Market Ecosystem Overview
TABLE 6: U.S. IVD Consumables Market: Stakeholder Analysis
TABLE 7: U.S. IVD Consumables Market: Executive Summary Snapshot, 2025
TABLE 8: U.S. IVD Consumables Market: Analyst Viewpoint Summary
TABLE 9: U.S. IVD Consumables Market: Market Attractiveness Index
TABLE 10: U.S. IVD Consumables Market: Historical Market Size, 2021–2024 (US$ Billion)
TABLE 11: U.S. IVD Consumables Market: Base Year Market Positioning, 2025
TABLE 12: U.S. IVD Consumables Market: Forecast Market Size, 2026–2035 (US$ Billion)
TABLE 13: U.S. IVD Consumables Market: Year-wise Market Size, 2021–2035 (US$ Billion)
TABLE 14: U.S. IVD Consumables Market: Drivers; Impact Analysis
TABLE 15: U.S. IVD Consumables Market: Restraints; Impact Analysis
TABLE 16: U.S. IVD Consumables Market: Opportunities; Impact Analysis
TABLE 17: U.S. IVD Consumables Market: Challenges; Impact Analysis
TABLE 18: U.S. IVD Consumables Market: Patent & Innovation Analysis, 2021–2025
TABLE 19: U.S. IVD Consumables Market: Clinical Laboratory Workflow Economics Matrix
TABLE 20: U.S. IVD Consumables Market: Cost per Reportable Result Analysis
TABLE 21: U.S. IVD Consumables Market: Reagent Utilization and Waste Economics
TABLE 22: U.S. IVD Consumables Market: Analyzer Installed-Base and Consumable Pull-Through Analysis
TABLE 23: U.S. IVD Consumables Market: Laboratory Procurement and Vendor Standardization Matrix
TABLE 24: U.S. IVD Consumables Market: Chronic Disease Testing Demand Indicators
TABLE 25: U.S. IVD Consumables Market: Molecular and Decentralized Testing Opportunity Matrix
TABLE 26: U.S. IVD Consumables Market: PESTEL Analysis
TABLE 27: U.S. IVD Consumables Market: Porter’s Five Forces Analysis
TABLE 28: U.S. IVD Consumables Market: Pricing Trend Analysis by Region, 2025–2035
TABLE 29: U.S. IVD Consumables Market: Value Chain Analysis
TABLE 30: U.S. IVD Consumables Market: Supply Chain Analysis
TABLE 31: U.S. IVD Consumables Market: Laboratory Automation and Digitalization Impact
TABLE 32: U.S. IVD Consumables Market: Application & Innovation Landscape
TABLE 33: U.S. IVD Consumables Market: FDA IVD Regulatory Framework Analysis
TABLE 34: U.S. IVD Consumables Market: Laboratory-Developed Test Regulatory Landscape
TABLE 35: U.S. IVD Consumables Market: CLIA Compliance and Laboratory Complexity Framework
TABLE 36: U.S. IVD Consumables Market: CMS Clinical Laboratory Fee Schedule Landscape
TABLE 37: U.S. IVD Consumables Market: PAMA and Private-Payer Data Impact Analysis
TABLE 38: U.S. IVD Consumables Market: Import/Export Restrictions & Tariff Impact
TABLE 39: U.S. IVD Consumables Market: Government Initiatives and Public Health Testing Programs
TABLE 40: U.S. IVD Consumables Market: Impact of Escalating Geopolitical Tensions
TABLE 41: U.S. IVD Consumables Market: Laboratory Value Analysis and Procurement Decision Framework
TABLE 42: U.S. IVD Consumables Market: Reagent-Rental and Analyzer Placement Economics
TABLE 43: U.S. IVD Consumables Market: Specialty Reagent and Raw Material Supply Risk Matrix
TABLE 44: U.S. IVD Consumables Market: Regulatory, Reimbursement and Market Access Matrix
TABLE 45: U.S. IVD Consumables Market: Product Type Snapshot, 2025
TABLE 46: Segment Dashboard; Definition and Scope, by Product Type
TABLE 47: U.S. IVD Consumables Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 48: U.S. IVD Consumables Market: Segment Share Analysis, by Product Type, 2025 & 2035 (%)
TABLE 49: U.S. IVD Consumables Market: Reagents and Assay Kits Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 50: U.S. IVD Consumables Market: Cartridges, Cassettes, Test Strips and Single-Use Test Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 51: U.S. IVD Consumables Market: Calibrators and Quality-Control Materials Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 52: U.S. IVD Consumables Market: Sample Preparation and Extraction Consumables Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 53: U.S. IVD Consumables Market: Specimen Collection, Transport and Ancillary Consumables Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 54: U.S. IVD Consumables Market: Diagnostic Technology Snapshot, 2025
TABLE 55: Segment Dashboard; Definition and Scope, by Diagnostic Technology
TABLE 56: U.S. IVD Consumables Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 57: U.S. IVD Consumables Market: Segment Share Analysis, by Diagnostic Technology, 2025 & 2035 (%)
TABLE 58: U.S. IVD Consumables Market: Immunoassay Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 59: U.S. IVD Consumables Market: Clinical Chemistry Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 60: U.S. IVD Consumables Market: Molecular Diagnostics and PCR Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 61: U.S. IVD Consumables Market: Hematology and Coagulation Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 62: U.S. IVD Consumables Market: Microbiology Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 63: U.S. IVD Consumables Market: Urinalysis and Other Specialized Diagnostics Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 64: U.S. IVD Consumables Market: Application Snapshot, 2025
TABLE 65: Segment Dashboard; Definition and Scope, by Application
TABLE 66: U.S. IVD Consumables Market, by Application, 2021–2035 (US$ Billion)
TABLE 67: U.S. IVD Consumables Market: Segment Share Analysis, by Application, 2025 & 2035 (%)
TABLE 68: U.S. IVD Consumables Market: Infectious Diseases Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 69: U.S. IVD Consumables Market: Diabetes and Metabolic Disorders Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 70: U.S. IVD Consumables Market: Oncology and Companion Diagnostics Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 71: U.S. IVD Consumables Market: Cardiovascular and Critical Care Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 72: U.S. IVD Consumables Market: Renal, Liver and Other Chronic Disease Testing Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 73: U.S. IVD Consumables Market: Women’s Health, Genetic and Reproductive Testing Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 74: U.S. IVD Consumables Market: End User Snapshot, 2025
TABLE 75: Segment Dashboard; Definition and Scope, by End User
TABLE 76: U.S. IVD Consumables Market, by End User, 2021–2035 (US$ Billion)
TABLE 77: U.S. IVD Consumables Market: Segment Share Analysis, by End User, 2025 & 2035 (%)
TABLE 78: U.S. IVD Consumables Market: Hospitals and Hospital Laboratories Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 79: U.S. IVD Consumables Market: Independent and Reference Laboratories Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 80: U.S. IVD Consumables Market: Physician Offices, Urgent Care and Near-Patient Testing Sites Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 81: U.S. IVD Consumables Market: Retail, Pharmacy and Home Testing Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 82: U.S. IVD Consumables Market: Public Health, Blood Banks, Academic and Specialty Laboratories Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 83: U.S. IVD Consumables Market: Procurement Channel Snapshot, 2025
TABLE 84: Segment Dashboard; Definition and Scope, by Procurement Channel
TABLE 85: U.S. IVD Consumables Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 86: U.S. IVD Consumables Market: Segment Share Analysis, by Procurement Channel, 2025 & 2035 (%)
TABLE 87: U.S. IVD Consumables Market: Direct Manufacturer and Health System Contracts Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 88: U.S. IVD Consumables Market: Reagent-Rental and Analyzer Placement Agreements Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 89: U.S. IVD Consumables Market: Group Purchasing Organization and IDN Contracts Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 90: U.S. IVD Consumables Market: Distributor and Specialty Laboratory Supplier Sales Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 91: U.S. IVD Consumables Market: Retail, Pharmacy, E-Commerce and Direct-to-Consumer Channels Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 92: U.S. IVD Consumables Market: Regional Snapshot, 2025
TABLE 93: Segment Dashboard; Definition and Scope, by Region
TABLE 94: U.S. IVD Consumables Market, by Region, 2021–2035 (US$ Billion)
TABLE 95: U.S. IVD Consumables Market: Regional Share Analysis, 2025 & 2035 (%)
TABLE 96: West Region U.S. IVD Consumables Market: Regional Overview and Trends
TABLE 97: West Region U.S. IVD Consumables Market: Key Manufacturers, Laboratories and Procurement Ecosystem
TABLE 98: West Region U.S. IVD Consumables Market, by State, 2021–2035 (US$ Billion)
TABLE 99: West Region U.S. IVD Consumables Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 100: West Region U.S. IVD Consumables Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 101: West Region U.S. IVD Consumables Market, by Application, 2021–2035 (US$ Billion)
TABLE 102: West Region U.S. IVD Consumables Market, by End User, 2021–2035 (US$ Billion)
TABLE 103: West Region U.S. IVD Consumables Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 104: California IVD Consumables Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 105: California IVD Consumables Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 106: California IVD Consumables Market, by Application, 2021–2035 (US$ Billion)
TABLE 107: California IVD Consumables Market, by End User, 2021–2035 (US$ Billion)
TABLE 108: California IVD Consumables Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 109: Washington IVD Consumables Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 110: Washington IVD Consumables Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 111: Washington IVD Consumables Market, by Application, 2021–2035 (US$ Billion)
TABLE 112: Washington IVD Consumables Market, by End User, 2021–2035 (US$ Billion)
TABLE 113: Washington IVD Consumables Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 114: Arizona IVD Consumables Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 115: Arizona IVD Consumables Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 116: Arizona IVD Consumables Market, by Application, 2021–2035 (US$ Billion)
TABLE 117: Arizona IVD Consumables Market, by End User, 2021–2035 (US$ Billion)
TABLE 118: Arizona IVD Consumables Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 119: Colorado IVD Consumables Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 120: Colorado IVD Consumables Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 121: Colorado IVD Consumables Market, by Application, 2021–2035 (US$ Billion)
TABLE 122: Colorado IVD Consumables Market, by End User, 2021–2035 (US$ Billion)
TABLE 123: Colorado IVD Consumables Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 124: Oregon IVD Consumables Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 125: Oregon IVD Consumables Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 126: Oregon IVD Consumables Market, by Application, 2021–2035 (US$ Billion)
TABLE 127: Oregon IVD Consumables Market, by End User, 2021–2035 (US$ Billion)
TABLE 128: Oregon IVD Consumables Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 129: Utah IVD Consumables Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 130: Utah IVD Consumables Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 131: Utah IVD Consumables Market, by Application, 2021–2035 (US$ Billion)
TABLE 132: Utah IVD Consumables Market, by End User, 2021–2035 (US$ Billion)
TABLE 133: Utah IVD Consumables Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 134: Nevada IVD Consumables Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 135: Nevada IVD Consumables Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 136: Nevada IVD Consumables Market, by Application, 2021–2035 (US$ Billion)
TABLE 137: Nevada IVD Consumables Market, by End User, 2021–2035 (US$ Billion)
TABLE 138: Nevada IVD Consumables Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 139: New Mexico IVD Consumables Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 140: New Mexico IVD Consumables Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 141: New Mexico IVD Consumables Market, by Application, 2021–2035 (US$ Billion)
TABLE 142: New Mexico IVD Consumables Market, by End User, 2021–2035 (US$ Billion)
TABLE 143: New Mexico IVD Consumables Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 144: Idaho IVD Consumables Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 145: Idaho IVD Consumables Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 146: Idaho IVD Consumables Market, by Application, 2021–2035 (US$ Billion)
TABLE 147: Idaho IVD Consumables Market, by End User, 2021–2035 (US$ Billion)
TABLE 148: Idaho IVD Consumables Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 149: Montana IVD Consumables Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 150: Montana IVD Consumables Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 151: Montana IVD Consumables Market, by Application, 2021–2035 (US$ Billion)
TABLE 152: Montana IVD Consumables Market, by End User, 2021–2035 (US$ Billion)
TABLE 153: Montana IVD Consumables Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 154: Wyoming IVD Consumables Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 155: Wyoming IVD Consumables Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 156: Wyoming IVD Consumables Market, by Application, 2021–2035 (US$ Billion)
TABLE 157: Wyoming IVD Consumables Market, by End User, 2021–2035 (US$ Billion)
TABLE 158: Wyoming IVD Consumables Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 159: Alaska IVD Consumables Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 160: Alaska IVD Consumables Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 161: Alaska IVD Consumables Market, by Application, 2021–2035 (US$ Billion)
TABLE 162: Alaska IVD Consumables Market, by End User, 2021–2035 (US$ Billion)
TABLE 163: Alaska IVD Consumables Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 164: Hawaii IVD Consumables Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 165: Hawaii IVD Consumables Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 166: Hawaii IVD Consumables Market, by Application, 2021–2035 (US$ Billion)
TABLE 167: Hawaii IVD Consumables Market, by End User, 2021–2035 (US$ Billion)
TABLE 168: Hawaii IVD Consumables Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 169: Northeast Region U.S. IVD Consumables Market: Regional Overview and Trends
TABLE 170: Northeast Region U.S. IVD Consumables Market: Key Manufacturers, Laboratories and Procurement Ecosystem
TABLE 171: Northeast Region U.S. IVD Consumables Market, by State, 2021–2035 (US$ Billion)
TABLE 172: Northeast Region U.S. IVD Consumables Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 173: Northeast Region U.S. IVD Consumables Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 174: Northeast Region U.S. IVD Consumables Market, by Application, 2021–2035 (US$ Billion)
TABLE 175: Northeast Region U.S. IVD Consumables Market, by End User, 2021–2035 (US$ Billion)
TABLE 176: Northeast Region U.S. IVD Consumables Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 177: New York IVD Consumables Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 178: New York IVD Consumables Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 179: New York IVD Consumables Market, by Application, 2021–2035 (US$ Billion)
TABLE 180: New York IVD Consumables Market, by End User, 2021–2035 (US$ Billion)
TABLE 181: New York IVD Consumables Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 182: Massachusetts IVD Consumables Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 183: Massachusetts IVD Consumables Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 184: Massachusetts IVD Consumables Market, by Application, 2021–2035 (US$ Billion)
TABLE 185: Massachusetts IVD Consumables Market, by End User, 2021–2035 (US$ Billion)
TABLE 186: Massachusetts IVD Consumables Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 187: New Jersey IVD Consumables Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 188: New Jersey IVD Consumables Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 189: New Jersey IVD Consumables Market, by Application, 2021–2035 (US$ Billion)
TABLE 190: New Jersey IVD Consumables Market, by End User, 2021–2035 (US$ Billion)
TABLE 191: New Jersey IVD Consumables Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 192: Pennsylvania IVD Consumables Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 193: Pennsylvania IVD Consumables Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 194: Pennsylvania IVD Consumables Market, by Application, 2021–2035 (US$ Billion)
TABLE 195: Pennsylvania IVD Consumables Market, by End User, 2021–2035 (US$ Billion)
TABLE 196: Pennsylvania IVD Consumables Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 197: Connecticut IVD Consumables Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 198: Connecticut IVD Consumables Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 199: Connecticut IVD Consumables Market, by Application, 2021–2035 (US$ Billion)
TABLE 200: Connecticut IVD Consumables Market, by End User, 2021–2035 (US$ Billion)
TABLE 201: Connecticut IVD Consumables Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 202: Maine IVD Consumables Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 203: Maine IVD Consumables Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 204: Maine IVD Consumables Market, by Application, 2021–2035 (US$ Billion)
TABLE 205: Maine IVD Consumables Market, by End User, 2021–2035 (US$ Billion)
TABLE 206: Maine IVD Consumables Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 207: Vermont IVD Consumables Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 208: Vermont IVD Consumables Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 209: Vermont IVD Consumables Market, by Application, 2021–2035 (US$ Billion)
TABLE 210: Vermont IVD Consumables Market, by End User, 2021–2035 (US$ Billion)
TABLE 211: Vermont IVD Consumables Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 212: New Hampshire IVD Consumables Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 213: New Hampshire IVD Consumables Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 214: New Hampshire IVD Consumables Market, by Application, 2021–2035 (US$ Billion)
TABLE 215: New Hampshire IVD Consumables Market, by End User, 2021–2035 (US$ Billion)
TABLE 216: New Hampshire IVD Consumables Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 217: Rhode Island IVD Consumables Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 218: Rhode Island IVD Consumables Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 219: Rhode Island IVD Consumables Market, by Application, 2021–2035 (US$ Billion)
TABLE 220: Rhode Island IVD Consumables Market, by End User, 2021–2035 (US$ Billion)
TABLE 221: Rhode Island IVD Consumables Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 222: Delaware IVD Consumables Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 223: Delaware IVD Consumables Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 224: Delaware IVD Consumables Market, by Application, 2021–2035 (US$ Billion)
TABLE 225: Delaware IVD Consumables Market, by End User, 2021–2035 (US$ Billion)
TABLE 226: Delaware IVD Consumables Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 227: South Region U.S. IVD Consumables Market: Regional Overview and Trends
TABLE 228: South Region U.S. IVD Consumables Market: Key Manufacturers, Laboratories and Procurement Ecosystem
TABLE 229: South Region U.S. IVD Consumables Market, by State, 2021–2035 (US$ Billion)
TABLE 230: South Region U.S. IVD Consumables Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 231: South Region U.S. IVD Consumables Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 232: South Region U.S. IVD Consumables Market, by Application, 2021–2035 (US$ Billion)
TABLE 233: South Region U.S. IVD Consumables Market, by End User, 2021–2035 (US$ Billion)
TABLE 234: South Region U.S. IVD Consumables Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 235: Texas IVD Consumables Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 236: Texas IVD Consumables Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 237: Texas IVD Consumables Market, by Application, 2021–2035 (US$ Billion)
TABLE 238: Texas IVD Consumables Market, by End User, 2021–2035 (US$ Billion)
TABLE 239: Texas IVD Consumables Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 240: Florida IVD Consumables Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 241: Florida IVD Consumables Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 242: Florida IVD Consumables Market, by Application, 2021–2035 (US$ Billion)
TABLE 243: Florida IVD Consumables Market, by End User, 2021–2035 (US$ Billion)
TABLE 244: Florida IVD Consumables Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 245: Georgia IVD Consumables Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 246: Georgia IVD Consumables Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 247: Georgia IVD Consumables Market, by Application, 2021–2035 (US$ Billion)
TABLE 248: Georgia IVD Consumables Market, by End User, 2021–2035 (US$ Billion)
TABLE 249: Georgia IVD Consumables Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 250: North Carolina IVD Consumables Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 251: North Carolina IVD Consumables Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 252: North Carolina IVD Consumables Market, by Application, 2021–2035 (US$ Billion)
TABLE 253: North Carolina IVD Consumables Market, by End User, 2021–2035 (US$ Billion)
TABLE 254: North Carolina IVD Consumables Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 255: Tennessee IVD Consumables Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 256: Tennessee IVD Consumables Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 257: Tennessee IVD Consumables Market, by Application, 2021–2035 (US$ Billion)
TABLE 258: Tennessee IVD Consumables Market, by End User, 2021–2035 (US$ Billion)
TABLE 259: Tennessee IVD Consumables Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 260: South Carolina IVD Consumables Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 261: South Carolina IVD Consumables Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 262: South Carolina IVD Consumables Market, by Application, 2021–2035 (US$ Billion)
TABLE 263: South Carolina IVD Consumables Market, by End User, 2021–2035 (US$ Billion)
TABLE 264: South Carolina IVD Consumables Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 265: Alabama IVD Consumables Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 266: Alabama IVD Consumables Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 267: Alabama IVD Consumables Market, by Application, 2021–2035 (US$ Billion)
TABLE 268: Alabama IVD Consumables Market, by End User, 2021–2035 (US$ Billion)
TABLE 269: Alabama IVD Consumables Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 270: Mississippi IVD Consumables Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 271: Mississippi IVD Consumables Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 272: Mississippi IVD Consumables Market, by Application, 2021–2035 (US$ Billion)
TABLE 273: Mississippi IVD Consumables Market, by End User, 2021–2035 (US$ Billion)
TABLE 274: Mississippi IVD Consumables Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 275: Louisiana IVD Consumables Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 276: Louisiana IVD Consumables Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 277: Louisiana IVD Consumables Market, by Application, 2021–2035 (US$ Billion)
TABLE 278: Louisiana IVD Consumables Market, by End User, 2021–2035 (US$ Billion)
TABLE 279: Louisiana IVD Consumables Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 280: Arkansas IVD Consumables Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 281: Arkansas IVD Consumables Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 282: Arkansas IVD Consumables Market, by Application, 2021–2035 (US$ Billion)
TABLE 283: Arkansas IVD Consumables Market, by End User, 2021–2035 (US$ Billion)
TABLE 284: Arkansas IVD Consumables Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 285: Kentucky IVD Consumables Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 286: Kentucky IVD Consumables Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 287: Kentucky IVD Consumables Market, by Application, 2021–2035 (US$ Billion)
TABLE 288: Kentucky IVD Consumables Market, by End User, 2021–2035 (US$ Billion)
TABLE 289: Kentucky IVD Consumables Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 290: Oklahoma IVD Consumables Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 291: Oklahoma IVD Consumables Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 292: Oklahoma IVD Consumables Market, by Application, 2021–2035 (US$ Billion)
TABLE 293: Oklahoma IVD Consumables Market, by End User, 2021–2035 (US$ Billion)
TABLE 294: Oklahoma IVD Consumables Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 295: Virginia IVD Consumables Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 296: Virginia IVD Consumables Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 297: Virginia IVD Consumables Market, by Application, 2021–2035 (US$ Billion)
TABLE 298: Virginia IVD Consumables Market, by End User, 2021–2035 (US$ Billion)
TABLE 299: Virginia IVD Consumables Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 300: Maryland IVD Consumables Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 301: Maryland IVD Consumables Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 302: Maryland IVD Consumables Market, by Application, 2021–2035 (US$ Billion)
TABLE 303: Maryland IVD Consumables Market, by End User, 2021–2035 (US$ Billion)
TABLE 304: Maryland IVD Consumables Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 305: West Virginia IVD Consumables Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 306: West Virginia IVD Consumables Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 307: West Virginia IVD Consumables Market, by Application, 2021–2035 (US$ Billion)
TABLE 308: West Virginia IVD Consumables Market, by End User, 2021–2035 (US$ Billion)
TABLE 309: West Virginia IVD Consumables Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 310: Midwest Region U.S. IVD Consumables Market: Regional Overview and Trends
TABLE 311: Midwest Region U.S. IVD Consumables Market: Key Manufacturers, Laboratories and Procurement Ecosystem
TABLE 312: Midwest Region U.S. IVD Consumables Market, by State, 2021–2035 (US$ Billion)
TABLE 313: Midwest Region U.S. IVD Consumables Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 314: Midwest Region U.S. IVD Consumables Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 315: Midwest Region U.S. IVD Consumables Market, by Application, 2021–2035 (US$ Billion)
TABLE 316: Midwest Region U.S. IVD Consumables Market, by End User, 2021–2035 (US$ Billion)
TABLE 317: Midwest Region U.S. IVD Consumables Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 318: Illinois IVD Consumables Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 319: Illinois IVD Consumables Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 320: Illinois IVD Consumables Market, by Application, 2021–2035 (US$ Billion)
TABLE 321: Illinois IVD Consumables Market, by End User, 2021–2035 (US$ Billion)
TABLE 322: Illinois IVD Consumables Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 323: Ohio IVD Consumables Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 324: Ohio IVD Consumables Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 325: Ohio IVD Consumables Market, by Application, 2021–2035 (US$ Billion)
TABLE 326: Ohio IVD Consumables Market, by End User, 2021–2035 (US$ Billion)
TABLE 327: Ohio IVD Consumables Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 328: Michigan IVD Consumables Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 329: Michigan IVD Consumables Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 330: Michigan IVD Consumables Market, by Application, 2021–2035 (US$ Billion)
TABLE 331: Michigan IVD Consumables Market, by End User, 2021–2035 (US$ Billion)
TABLE 332: Michigan IVD Consumables Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 333: Minnesota IVD Consumables Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 334: Minnesota IVD Consumables Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 335: Minnesota IVD Consumables Market, by Application, 2021–2035 (US$ Billion)
TABLE 336: Minnesota IVD Consumables Market, by End User, 2021–2035 (US$ Billion)
TABLE 337: Minnesota IVD Consumables Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 338: Indiana IVD Consumables Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 339: Indiana IVD Consumables Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 340: Indiana IVD Consumables Market, by Application, 2021–2035 (US$ Billion)
TABLE 341: Indiana IVD Consumables Market, by End User, 2021–2035 (US$ Billion)
TABLE 342: Indiana IVD Consumables Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 343: Wisconsin IVD Consumables Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 344: Wisconsin IVD Consumables Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 345: Wisconsin IVD Consumables Market, by Application, 2021–2035 (US$ Billion)
TABLE 346: Wisconsin IVD Consumables Market, by End User, 2021–2035 (US$ Billion)
TABLE 347: Wisconsin IVD Consumables Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 348: Missouri IVD Consumables Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 349: Missouri IVD Consumables Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 350: Missouri IVD Consumables Market, by Application, 2021–2035 (US$ Billion)
TABLE 351: Missouri IVD Consumables Market, by End User, 2021–2035 (US$ Billion)
TABLE 352: Missouri IVD Consumables Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 353: Iowa IVD Consumables Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 354: Iowa IVD Consumables Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 355: Iowa IVD Consumables Market, by Application, 2021–2035 (US$ Billion)
TABLE 356: Iowa IVD Consumables Market, by End User, 2021–2035 (US$ Billion)
TABLE 357: Iowa IVD Consumables Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 358: Kansas IVD Consumables Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 359: Kansas IVD Consumables Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 360: Kansas IVD Consumables Market, by Application, 2021–2035 (US$ Billion)
TABLE 361: Kansas IVD Consumables Market, by End User, 2021–2035 (US$ Billion)
TABLE 362: Kansas IVD Consumables Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 363: Nebraska IVD Consumables Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 364: Nebraska IVD Consumables Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 365: Nebraska IVD Consumables Market, by Application, 2021–2035 (US$ Billion)
TABLE 366: Nebraska IVD Consumables Market, by End User, 2021–2035 (US$ Billion)
TABLE 367: Nebraska IVD Consumables Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 368: North Dakota IVD Consumables Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 369: North Dakota IVD Consumables Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 370: North Dakota IVD Consumables Market, by Application, 2021–2035 (US$ Billion)
TABLE 371: North Dakota IVD Consumables Market, by End User, 2021–2035 (US$ Billion)
TABLE 372: North Dakota IVD Consumables Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 373: South Dakota IVD Consumables Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 374: South Dakota IVD Consumables Market, by Diagnostic Technology, 2021–2035 (US$ Billion)
TABLE 375: South Dakota IVD Consumables Market, by Application, 2021–2035 (US$ Billion)
TABLE 376: South Dakota IVD Consumables Market, by End User, 2021–2035 (US$ Billion)
TABLE 377: South Dakota IVD Consumables Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 378: U.S. IVD Consumables Market: Competitive Landscape Snapshot, 2025
TABLE 379: U.S. IVD Consumables Market: Key Company Market Share Analysis, 2025
TABLE 380: U.S. IVD Consumables Market: Company Positioning Matrix
TABLE 381: U.S. IVD Consumables Market: Product Portfolio Benchmarking of Key Players
TABLE 382: U.S. IVD Consumables Market: Installed Analyzer Base and Reagent Pull-Through Benchmarking
TABLE 383: U.S. IVD Consumables Market: Competitive Pricing and Contracting Analysis
TABLE 384: U.S. IVD Consumables Market: Strategic Developments, Partnerships, Licensing, M&A and Product Launches
TABLE 385: Roche Diagnostics: Company Profile
TABLE 386: Abbott Laboratories: Company Profile
TABLE 387: Siemens Healthineers: Company Profile
TABLE 388: Beckman Coulter Diagnostics: Company Profile
TABLE 389: Cepheid: Company Profile
TABLE 390: Thermo Fisher Scientific: Company Profile
TABLE 391: Becton, Dickinson and Company: Company Profile
TABLE 392: bioMérieux: Company Profile
TABLE 393: QuidelOrtho: Company Profile
TABLE 394: Hologic: Company Profile
TABLE 395: QIAGEN: Company Profile
TABLE 396: Bio-Rad Laboratories: Company Profile
TABLE 397: Sysmex America: Company Profile
TABLE 398: Werfen: Company Profile
TABLE 399: DiaSorin: Company Profile
TABLE 400: Fujirebio Diagnostics: Company Profile
TABLE 401: Agilent Technologies: Company Profile
TABLE 402: Illumina: Company Profile
TABLE 403: Revvity: Company Profile
TABLE 404: SEKISUI Diagnostics: Company Profile
TABLE 405: Randox Laboratories: Company Profile
TABLE 406: Trinity Biotech: Company Profile
TABLE 407: Meridian Bioscience / SD Biosensor: Company Profile
TABLE 408: ARKRAY: Company Profile
TABLE 409: SEKISUI Medical / Specialty Diagnostic Operations: Company Profile
TABLE 410: U.S. IVD Consumables Market: Future Market Scenario Analysis, 2026–2035
TABLE 411: U.S. IVD Consumables Market: Disruptive Technologies Impact Matrix
TABLE 412: U.S. IVD Consumables Market: Emerging Business Trends
TABLE 413: U.S. IVD Consumables Market: Business Opportunities for Startups and Existing Players
TABLE 414: U.S. IVD Consumables Market: Investment Prioritization Matrix
TABLE 415: U.S. IVD Consumables Market: High-Growth Assay Opportunity Matrix
TABLE 416: U.S. IVD Consumables Market: Market White-Space Analysis
TABLE 417: U.S. IVD Consumables Market: Potential Market Disruption Risks Through 2035
TABLE 418: U.S. IVD Consumables Market: Strategic Recommendations for IVD Consumables Manufacturers
TABLE 419: U.S. IVD Consumables Market: Strategic Recommendations for Hospitals, Health Systems and Clinical Laboratories
TABLE 420: U.S. IVD Consumables Market: Strategic Recommendations for Independent and Reference Laboratories
TABLE 421: U.S. IVD Consumables Market: Strategic Recommendations for Investors and Private Equity Firms
TABLE 422: U.S. IVD Consumables Market: Strategic Recommendations for Distributors and Channel Partners
TABLE 423: U.S. IVD Consumables Market: Strategic Recommendations for New Entrants and Diagnostic Startups
TABLE 424: U.S. IVD Consumables Market: Go-to-Market Strategy Considerations
TABLE 425: U.S. IVD Consumables Market: Product Positioning and Test-Menu Expansion Guidance
TABLE 426: U.S. IVD Consumables Market: Analyzer Installed-Base Expansion Strategy
TABLE 427: U.S. IVD Consumables Market: Reagent-Rental and Cost-per-Test Contracting Strategy
TABLE 428: U.S. IVD Consumables Market: FDA, Reimbursement and Market-Access Strategy
TABLE 429: U.S. IVD Consumables Market: State and Regional Commercial Prioritization Strategy
TABLE 430: U.S. IVD Consumables Market: Scope Limitation
TABLE 431: U.S. IVD Consumables Market: Data Use Limitation
TABLE 432: U.S. IVD Consumables Market: Market Sizing and Forecasting Limitation
TABLE 433: U.S. IVD Consumables Market: Clinical and Regulatory Information Limitation
TABLE 434: U.S. IVD Consumables Market: Legal Disclaimer
TABLE 435: U.S. IVD Consumables Market: Third-Party Data Disclaimer

List of Figures

FIGURE 1: U.S. IVD Consumables Market Segmentation
FIGURE 2: Market Research Methodology
FIGURE 3: Market Ecosystem Overview
FIGURE 4: Stakeholder Analysis
FIGURE 5: Market Attractiveness Analysis
FIGURE 6: U.S. IVD Consumables Market Size, Historical Trend Analysis, 2021–2024 (US$ Billion)
FIGURE 7: U.S. IVD Consumables Market Size, Forecast and Trend Analysis, 2026–2035 (US$ Billion)
FIGURE 8: U.S. IVD Consumables Market Year-wise Growth Curve, 2021–2035
FIGURE 9: Recurring-Revenue and Installed-Base Economics Framework
FIGURE 10: Market Dynamics
FIGURE 11: Innovation & Patent Landscape, 2021–2025
FIGURE 12: Clinical Laboratory Workflow Economics Framework
FIGURE 13: Cost per Reportable Result Framework
FIGURE 14: Analyzer Installed-Base and Consumable Pull-Through Model
FIGURE 15: Laboratory Procurement and Vendor Standardization Framework
FIGURE 16: Value Chain Analysis
FIGURE 17: Supply Chain Analysis
FIGURE 18: PESTEL Analysis
FIGURE 19: Porter’s Five Forces Analysis
FIGURE 20: FDA, CLIA and Reimbursement Landscape
FIGURE 21: Reagent-Rental and Analyzer Placement Economics Framework
FIGURE 22: Product Type Segment Market Share Analysis, 2025 & 2035
FIGURE 23: Product Type Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 24: Reagents and Assay Kits Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 25: Cartridges, Cassettes, Test Strips and Single-Use Test Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 26: Calibrators and Quality-Control Materials Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 27: Sample Preparation and Extraction Consumables Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 28: Specimen Collection, Transport and Ancillary Consumables Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 29: Diagnostic Technology Segment Market Share Analysis, 2025 & 2035
FIGURE 30: Diagnostic Technology Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 31: Immunoassay Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 32: Clinical Chemistry Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 33: Molecular Diagnostics and PCR Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 34: Hematology and Coagulation Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 35: Microbiology Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 36: Urinalysis and Other Specialized Diagnostics Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 37: Application Segment Market Share Analysis, 2025 & 2035
FIGURE 38: Application Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 39: Infectious Diseases Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 40: Diabetes and Metabolic Disorders Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 41: Oncology and Companion Diagnostics Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 42: Cardiovascular and Critical Care Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 43: Renal, Liver and Other Chronic Disease Testing Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 44: Women’s Health, Genetic and Reproductive Testing Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 45: End User Segment Market Share Analysis, 2025 & 2035
FIGURE 46: End User Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 47: Hospitals and Hospital Laboratories Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 48: Independent and Reference Laboratories Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 49: Physician Offices, Urgent Care and Near-Patient Testing Sites Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 50: Retail, Pharmacy and Home Testing Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 51: Public Health, Blood Banks, Academic and Specialty Laboratories Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 52: Procurement Channel Segment Market Share Analysis, 2025 & 2035
FIGURE 53: Procurement Channel Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 54: Direct Manufacturer and Health System Contracts Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 55: Reagent-Rental and Analyzer Placement Agreements Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 56: Group Purchasing Organization and IDN Contracts Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 57: Distributor and Specialty Laboratory Supplier Sales Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 58: Retail, Pharmacy, E-Commerce and Direct-to-Consumer Channels Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 59: Regional Segment Market Share Analysis, 2025 & 2035
FIGURE 60: Regional Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 61: West Region U.S. IVD Consumables Market Share and Leading Players, 2025
FIGURE 62: West Region Market Share Analysis by State, 2025
FIGURE 63: West Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 64: California IVD Consumables Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 65: Washington IVD Consumables Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 66: Arizona IVD Consumables Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 67: Colorado IVD Consumables Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 68: Oregon IVD Consumables Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 69: Utah IVD Consumables Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 70: Nevada IVD Consumables Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 71: New Mexico IVD Consumables Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 72: Idaho IVD Consumables Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 73: Montana IVD Consumables Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 74: Wyoming IVD Consumables Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 75: Alaska IVD Consumables Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 76: Hawaii IVD Consumables Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 77: Northeast Region U.S. IVD Consumables Market Share and Leading Players, 2025
FIGURE 78: Northeast Region Market Share Analysis by State, 2025
FIGURE 79: Northeast Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 80: New York IVD Consumables Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 81: Massachusetts IVD Consumables Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 82: New Jersey IVD Consumables Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 83: Pennsylvania IVD Consumables Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 84: Connecticut IVD Consumables Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 85: Maine IVD Consumables Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 86: Vermont IVD Consumables Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 87: New Hampshire IVD Consumables Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 88: Rhode Island IVD Consumables Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 89: Delaware IVD Consumables Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 90: South Region U.S. IVD Consumables Market Share and Leading Players, 2025
FIGURE 91: South Region Market Share Analysis by State, 2025
FIGURE 92: South Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 93: Texas IVD Consumables Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 94: Florida IVD Consumables Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 95: Georgia IVD Consumables Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 96: North Carolina IVD Consumables Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 97: Tennessee IVD Consumables Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 98: South Carolina IVD Consumables Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 99: Alabama IVD Consumables Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 100: Mississippi IVD Consumables Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 101: Louisiana IVD Consumables Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 102: Arkansas IVD Consumables Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 103: Kentucky IVD Consumables Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 104: Oklahoma IVD Consumables Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 105: Virginia IVD Consumables Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 106: Maryland IVD Consumables Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 107: West Virginia IVD Consumables Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 108: Midwest Region U.S. IVD Consumables Market Share and Leading Players, 2025
FIGURE 109: Midwest Region Market Share Analysis by State, 2025
FIGURE 110: Midwest Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 111: Illinois IVD Consumables Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 112: Ohio IVD Consumables Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 113: Michigan IVD Consumables Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 114: Minnesota IVD Consumables Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 115: Indiana IVD Consumables Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 116: Wisconsin IVD Consumables Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 117: Missouri IVD Consumables Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 118: Iowa IVD Consumables Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 119: Kansas IVD Consumables Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 120: Nebraska IVD Consumables Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 121: North Dakota IVD Consumables Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 122: South Dakota IVD Consumables Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 123: Competitive Landscape; Key Company Market Share Analysis, 2025
FIGURE 124: Company Positioning Matrix
FIGURE 125: Key Player Product Portfolio Benchmarking
FIGURE 126: Installed Analyzer Base and Reagent Pull-Through Benchmarking
FIGURE 127: Competitive Pricing and Contracting Matrix
FIGURE 128: Strategic Developments, Partnerships, Licensing, M&A and Product Launches
FIGURE 129: IVD Consumables Innovation Roadmap
FIGURE 130: Future Market Scenario Analysis, 2026–2035
FIGURE 131: Disruptive Technologies Impact Matrix
FIGURE 132: Emerging Business Trends Matrix
FIGURE 133: High-Growth Assay Opportunity Map
FIGURE 134: Investment Prioritization Matrix
FIGURE 135: Market White-Space Opportunity Map
FIGURE 136: Decentralized and Molecular Testing Growth Roadmap
FIGURE 137: Potential Market Disruption Risk Matrix Through 2035
FIGURE 138: Strategic Growth Roadmap for U.S. IVD Consumables Companies
FIGURE 139: Go-to-Market Strategy Framework
FIGURE 140: Product Positioning and Test-Menu Expansion Framework
FIGURE 141: Analyzer Installed-Base Expansion Framework
FIGURE 142: Reagent-Rental and Cost-per-Test Contracting Framework
FIGURE 143: FDA, Reimbursement and Market-Access Strategy Framework
FIGURE 144: State and Regional Commercial Prioritization Matrix
FIGURE 145: Strategic Recommendations Framework by Stakeholder
FIGURE 146: Report Scope, Limitations and Disclaimer Framework